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OVERVIEW 
 
This thesis examines early diagnosis of dementia by understanding the impact Mild 
Cognitive Impairment has on quality of life (QoL) and the clinical utility of a newly 
developed instrument in aiding early diagnosis of AD by differentiating it from other forms 
of dementia. This thesis formed part of a wider PHD project that is still being completed. 
 
Part 1 is a literature review investigating the impact being diagnosed with Mild Cognitive 
Impairment (MCI) has on Quality of Life (QoL) in comparison to cognitively healthy 
controls and people with dementia. A total of 15 studies were examined. Overall, the 
evidence was inconsistent and methodological quality of the included research papers was 
weak. The review highlighted the need for further good quality research investigating the 
impact of MCI on QoL.   
 
 
Part 2 is an empirical paper that reports the findings of a study examining the clinical utility 
of the Four Mountains Test (4MT), a measurement of hippocampal dependent allocentric 
memory processing, in aiding early and differential diagnosis of AD. A total of 35 
participants with differing types of early dementia from a memory service completed the 
4MT alongside neuropsychological measures of memory, language, visuospatial, fluency, 
attention, executive function and premordid functioning. No significant results were found. 
Study implications and limitations are discussed with ideas for future research.  
 
Part 3 is a critical appraisal that provides reflections on the process of conducting the thesis. 
It discusses relevance of non-significant findings and potential of computer based tests such 
as the 4MT as well as the dilemmas encountered, methodological limitations and wider 
clinical implications of carrying out research with people with dementia.  
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ABSTRACT 
 
Background: The intermediate state between normal ageing and dementia, Mild Cognitive 
Impairment (MCI), has recently become a primary target of aging research. This has led to 
an interest in the quality of life (QoL) of people diagnosed with MCI.  
Aim: This review aimed to understand the impact having MCI has on QoL and factors that 
influence the extent to which QOL is affected. 
Method: A systematic literature search was conducted. Of 878 studies identified, 15 studies 
published between 1999 and 2014 met the inclusion criteria. Quality was rated using pre-
specified criteria. Studies were divided into the following categories based on QoL 
components covered: perceived QoL, psychological well-being and social relationships.  
Results: The evidence was highly inconsistent and of poor to adequate quality. Most studies 
found no evidence of differences in perceived QoL for MCI relative to dementia or normal 
cognition groups. However, there was evidence of a reduction in psychological well-being 
and social relationships in an MCI population. Conflicting evidence was found regarding the 
concordance of MCI informant and patient ratings of QoL. Depression was found to be a 
strong, consistent predictor of MCI impact on QoL across studies.   
Discussion: Inconsistent evidence and methodological weaknesses limit the conclusions 
drawn from the review about the impact of MCI on QoL. Longitudinal studies are needed 
before conclusive interpretations can be made. Implications of these findings for clinical 
practice are discussed alongside the limitations of the evidence base and future research 
directions. 
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INTRODUCTION 
 
Mild Cognitive Impairment  
Over the last decade much interest has developed in the intermediate state between healthy 
cognition and dementia, originating from a desire to identify individuals at risk of 
developing Alzheimer’s Dementia (AD). The term Mild Cognitive Impairment (MCI) is 
most frequently used to refer to a transitional zone between normal cognitive function and 
early AD (Petersen et al, 2001; Winbald et al; 2004; Albert et al, 2011). There has been an 
increase in the UK prevalence of people with MCI, affecting between 5 and 20 per cent of 
the population aged 65 or over (Ray & Davidson, 2014). However, with increased awareness 
of dementia and availability of memory services it has been stated that the rates of referral 
for assessment and, hence, diagnosis of MCI will increase in the UK in the coming years 
(Dean & Wilcock, 2012).  
 
Conversion to dementia  
There is research that has demonstrated a link between MCI and increased risk of 
progressing to probable AD (Lopez et al, 2003; Busse et al, 2006; Plassman et al, 2008; 
Manly et al, 2008). However, other studies examining the conversion rates of MCI to AD 
show that not all individuals with MCI go on to develop AD (Bruscoli & Lovestone, 2004; 
Koepsell & Monsell, 2012; Plassman et al, 2008; Mitchell & Shiri-Feshki, 2009). For 
example, in a population based sample of older adults 32% of individuals with MCI were 
diagnosed with AD five years later, 15% were diagnosed with other forms of dementia such 
as vascular dementia and some individuals recovered with time (Tuokko et al, 2005). Fisk 
and Rockwood (2007) found that 20-30% of individuals with MCI showed no cognitive 
impairment at follow up five years later. These results have led some researchers to suggest 
that MCI represents a heterogeneous disorder with various potential outcomes (Petersen et 
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al, 2014). 
 
Defining MCI  
There is significant heterogeneity in the criteria used to define MCI with subtle differences 
in the conceptualisations, which may contribute to differing estimates of prevalence, 
incidence and conversion rates (Kumar et al, 2005; Bischkopf et al, 2002; Ritchie et al, 
2001). Petersen et al (1999) first described MCI to identify individuals at risk of developing 
AD. The criteria emphasised the presence of a memory complaint in the absence of 
cognitive impairment, dementia and no deficits in activities of daily (ADLs). The criteria for 
MCI have since evolved following the formation of an international expert working group 
(Winbald et al, 2004; Petersen, 2003; 2004) that refined the criteria to reflect the 
heterogeneous clinical presentation of MCI. This resulted in the inclusion of other types of 
cognitive impairment beyond memory and minimal impairment to basic ADLs as well as 
preserved ADLs. The cognitive impairment is to be defined by either self and/or informant 
report in addition to evidence from objective measures of cognitive functioning.  
 
The most recent classification (Albert et al, 2011) also identifies three MCI subtypes: (1) 
MCI with a memory impairment (MCI amnestic); (2) MCI with impairment in a single non-
memory domain (non-amnestic MCI); (3) MCI with impairment in multiple cognitive 
domains e.g. language, executive function and visuospatial skills (multiple domain MCI). 
However, amnestic and non-amnestic MCI are most commonly used within the clinical and 
research field. The different subtypes likely reflect different aetiologies, including 
degenerative, vascular, psychiatric or trauma-related causes. For example, the amnestic MCI 
is thought to primarily constitute a prodromal phase of AD (Morris, 2006), whereas 
individuals with non-amnestic MCI may have higher likelihood of progression to other 
forms of dementia, such as vascular or fronto-temporal dementia. 
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Quality of Life in dementia 
Quality of Life (QoL) has increasingly become an important construct within healthcare in 
understanding the impact of diseases and associated treatments particularly for chronic 
disorders (Muldoon et al, 1998). In the UK it is estimated that over 750,000 people have 
dementia and that this number is expected to double in the next thirty years (Department of 
Health, 2009). In line with this, there has been an increased interest in the QoL of older 
people with dementia or other forms of cognitive impairment (Whitehouse, 1999). 
Maximising and maintaining the well-being of both people with cognitive impairment and 
their carers has become a primary aim for dementia treatment in the absence of biological 
treatments for the underlying disease processes (Logsdon, McCurry & Teri, 2007). QoL has 
therefore been identified as an important domain for dementia assessment and treatment 
outcome (Lawton, 1994). The cognitive, behavioural, and functional symptoms seen in 
dementia can significantly impact patients’ general well-being or QoL. Multiple studies 
using various rating scales to measure QoL have demonstrated decreased QoL in 
participantss with dementia compared to those without cognitive impairment (Thorgrimsen 
et al, 2003; Ready et al, 2004; Ettema et al, 2005; Vogel, Mortensen et al, 2006; Missotten et 
al, 2008; Hurt et al., 2008; Conde-Sala et al 2009; Rosas-Carrasco et al, 2010; Lapid et al; 
2011)  
 
Definitions of QoL in dementia 
QoL is a complex multi-dimensional construct and therefore defining QoL in dementia is 
challenging due to the variety of relevant life domains affected dependent on the different 
stages of the disease or type of dementia. A variety of definitions have been proposed which 
vary significantly in the breadth of domains incorporated and there is still to date no single 
consensus definition of QoL available. There has been significant disagreement about how 
broad QoL should be as a construct. Broader definitions have been considered problematic 
blurring the line between what constitutes the symptoms and signs of dementia (i.e. memory 
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loss, functional impairment) and QoL. Narrower definitions of QoL tend to be considered 
more accessible allowing a more straightforward exploration of the relationship between 
QoL and dementia (Ready et al, 2004). Despite this lack of general consensus, there have 
been some areas of agreement of components that are critical to consider and supported by 
research. These universally recognised components of QoL include mood, preserved 
positive affect (i.e. pleasure, interest and contentment), absence of negative affect (e.g. 
anger, anxiety, and depression) and interpersonal relationships (Albert et al, 1996; Brod et 
al, 1999; Weiner et al, 2000; Burgener and Twigg, 2002; Logsdon et al, 2002; Ready et al, 
2004).  
 
Measurement of QoL in dementia 
Measuring QoL in people with cognitive impairment presents a challenge due to its 
subjective nature and subsequent reliance on self-perceptions (Frank et al, 2011). As a 
person’s dementia progresses cognitive and memory impairments lead to a reduction of 
insight into their deficits. Self-ratings of QoL may not therefore accurately reflect their 
abilities and recent experiences. In light of this, many scales involve a caregiver’s 
perspective to allow clarification about events that the person may have forgotten. 
Additionally, this provides an opportunity for an examination of the differences and 
similarities between patient and caregiver perceptions of QoL. A number of QoL 
measurement tools have been developed over the years that involve a range of assessment 
methods (i.e. self ratings, informant ratings, direct observation; Lodgson et al, 2002). A 
comprehensive evaluation of QoL should consist of both self-administered and objective 
proxy assessment. Direct assessment of QoL of patients with dementia may be reliable in the 
earlier stages of illness (Brod et al, 1999). The assessment method selected is often 
dependent on the stage of dementia the measure is attempting to target. Research has 
demonstrated that people with a Mini Mental State Examination (MMSE; Folstein, Folstein & 
McHugh, 1975) score of 10 or greater can usually participate in an interview about their 
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QoL to some degree that are as reliable as carer reports (Logsdon et al, 2000; Brod et al, 
1999; Selai et al, 2000). In light of this, when measuring QoL in milder dementia or MCI it 
is particularly important to use measures that incorporate input from the person. 
 
QoL in MCI 
Research has demonstrated that the cognitive, behavioural and functional symptoms 
associated with dementia can significantly impact general well-being and QoL (Teng et al, 
2012). Given that the symptoms consistent with early dementia are also often present in 
MCI, reductions in QoL might also be expected in this population. However, no specific 
tools have been designed to assess QoL in MCI. Given the crossover of MCI symptoms with 
early AD many studies have used measures designed to assess QoL in a dementia population 
e.g. QoL-AD (Tatsumi et al, 2011). A number of studies have investigated the impact having 
MCI has on QoL compared to healthy cognition and/or dementia. A better understanding of 
the impact of MCI on QoL may allow for more refined support from health services to 
maximize and maintain well-being. However, to date there has been no review of studies 
that have explored the impact of QoL in an MCI population and any potential determinants.  
 
Current Literature Review 
There has been no review to date that has specifically investigated the impact on QoL for 
people with MCI and how this compares to older people with no cognitive impairment or 
dementia. Dean and Wilcock (2012) conducted a review that focused on the experiences of 
living with MCI and found that MCI patients and carers encountered a range of cognitive, 
neuropsychiatric and practical issues. However, this review did not specifically review 
studies using QoL as the main outcome and solely from a quantitative perspective. Other 
previous reviews have specifically focused on understanding the prevalence of 
neuropsychiatric symptoms in an MCI population finding higher levels of mood 
disturbances (e.g. depression, anxiety) (Apostolova & Cummings, 2008; Yates et al, 2013; 
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Seeher, Low & Reppermund, 2013). Previous reviews have not directly investigated how 
QoL and the specific components that contribute to QoL are affected in MCI as well as any 
associated factors that may predict the degree of impact on QoL in MCI. In of light of this, 
the perceived aim of this review was to summarise quantitative evidence exploring the QoL 
of people with MCI from the patient perspective.   
 
Literature review questions 
The review addressed the following research questions: 
1. Do differences in ratings of perceived QoL exist between individuals with MCI and 
those with no cognitive impairment or dementia? 
2. How are specific aspects of QoL (i.e. psychological well-being and social relationships) 
affected by MCI and how do these differ from those with no cognitive impairment or 
dementia? 
3. Do differences exist between self and informant ratings of QoL in MCI?  
4. Are there any factors that predict the impact of MCI on QoL? 
 
 
 
 
 
 
 
 
 
 
 
 
!"&!
METHOD 
 
Search Strategy  
A 3-step search strategy was utilised in this review. An initial limited search of Psychinfo 
was undertaken followed by analysis of the text words contained in the title and abstract, and 
of the subject headings used to describe an article. A second search using all identified 
keywords and subject heading relevant to the specific databases was then undertaken across 
all included databases in January 2015. The following electronic databases were searched for 
studies: Psychinfo, Web of Science, Medline, CINAHL and EMBASE databases. Keywords 
were entered to request studies involving people diagnosed with MCI (Mild Cognitive 
Impairment, MCI) and the perspective (patient, client, elderly, older adult, geriatric). 
Keywords were also used to identify studies evaluating the impact on QoL (quality of life, 
QoL, well-being, satisfaction, life). In order to focus the review on recent evidence in the 
field, only studies published between 1999 to present were included in the review. This date 
was selected because there was an emergence of research in the dementia field after Petersen 
(1999) published his diagnostic criteria defining MCI as a clinical entity. Furthermore, when 
running the search there were only 4 papers published before 1999 that were unrelated to 
QoL in an MCI population. Titles, abstracts and excerpts were reviewed according to the 
inclusion and exclusion criteria (see below). The reference lists of articles meeting the 
inclusion criteria were also reviewed to identify additional publications. Studies were 
required to meet the following criteria to be included in the review:  
 
Inclusion Criteria 
, Included studies investigating QoL as a primary outcome  
, Included studies investigating specific components of QoL: psychological well-being 
(i.e. depression, positive affect, negative affect) or social relationships 
, Included studies evaluating patients perspectives alongside carer/informant perspectives 
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, Included studies that employed quantitative measures and data analysis  
, Included journals published between 1999 to present (as stated above) in English and in 
peer- reviewed journals 
 
Exclusion Criteria  
, Excluded studies looking exclusively at a dementia population 
, Excluded neuropsychological studies of MCI concerning cognitive features and abilities 
, Excluded biologically based studies of MCI concerning brain pathology, physiology or  
genetics  
, Excluded studies concerned with psychosocial or drug interventions 
, Excluded studies that included only carer perspectives 
, Excluded studies that had taken place within care homes and acute geriatric services 
, Excluded studies addressing QoL measure design and validation 
, Excluded studies in languages other than English  
, Excluded studies employing qualitative measures and data analysis methods 
, Excluded editorials, reviews, commentaries, letters or other articles that contained no 
original data  
, Excluded studies published before 1999 
, Excluded dissertation or conference papers 
, Excluded single case study design 
 
Data extraction 
Information was extracted from eligible studies on country of study, design, population age, 
sample size, participant source, diagnostic criteria, components and measurement of QoL, 
confounders adjusted for and main findings. The author extracted data independently. 
 
Quality Assessment 
!"(!
The quality of the studies were rated using the adapted Newcastle Ottawa Scale (NOS) for 
cross-sectional studies (Wells et al, 2000) (see Appendix 1). It was developed to assess the 
quality of design and content of non-randomised studies for systematic literature review 
results in an efficient way. A quality score is calculated based on three major components: 
(1) selection of the groups of study, (2) comparability, (3) assessment of the outcome or 
exposure. A 'star system' is used to judge the three broad categories on a scale from 0 
(poorest quality) to 9 (highest quality). In this review, the studies were classified into groups 
based on cut off scores which have been used in previous research that used the NOS to rate 
methodological quality (Backhaus et al, 2014). The categories included poor (less than 3 
stars), adequate (4–7 stars), or high (8–9 stars) quality (see Table 3 for quality scores).  
 
Classification of QoL studies in specific areas 
It was necessary to classify studies in accordance with the different components of QoL to 
usefully compare the studies included in the review. Studies assessing perceived QoL within 
an MCI population comprised the first category. Additionally, studies were divided into two 
further categories that related to the specific components that contribute to perceived QoL in 
line with research; psychological well-being (i.e. mood, positive and negative affect) and 
social relationships (Albert et al, 1996; Brod et al, 1999; Weiner et al, 2000; Burgener & 
Twigg, 2002; Logsdon et al, 2002; Ready et al, 2004). The review did also consider in less 
depth other components of QoL that were assessed in specific QoL measures (e.g. QoL-AD) 
such as physical health, self-efficacy.  
 
Potential predictors of QoL components were also identified and catergorised into 3 
categories based on Pearson’s correlation co-efficient strength (Taylor, 1990). Correlations 
were therefore classified accordingly: weak (+/- 0.2 to 0.29), moderate (+/- 0.3 and 0.39), 
strong (above +/- 0.4). Correlations below 0.2 were classified as no relationship and 
therefore were not considered possible predictors. 
!")!
RESULTS 
 
Overview of results  
A total of 878 articles were identified from the database search. The final review included 15 
studies; the database search yielded 12 studies with a further 3 studies identified from 
reference lists. The remaining studies were excluded because they were unrelated to the QoL 
topic being reviewed (761) or investigated QoL exclusively within a dementia population 
(31) as well as other clinical populations (4). In addition, studies were excluded if they 
included exclusively carer’s perspective (2) or were conducted in acute care settings (2). 
Neuropsychological (19), biological (9) and treatment (13) studies concerned with MCI 
and/or QoL were also excluded from the review. Furthermore, studies concerned with QoL 
measure development and validation were also excluded even if involving an MCI 
population (5). The remaining studies were either not published in English (5), were 
dissertation or conference papers (4) or did not include original data i.e. review articles, 
book chapters or case studies (5). No studies were excluded due to study design (see figure 1 
for overview of review process). The studies were conducted across a variety of different 
countries within Europe, USA and South East Asia (see table 3).  
 
 
 
 
 
 
 
 
 
 
!"*!
Figure 1: Flow chart of review process 
 
 
 
 
 
 
 
 
 
Study design and quality  
Fifteen cross-sectional studies were included in the review. According to the NOS criteria, 9 
studies were rated as adequate quality and 6 studies were rated as poor quality (see Table 3). 
Cross-sectional studies are susceptible to bias due to comparison of different population 
groups at a single point in time without manipulation of variables. It is therefore 
!
Records identified through database searching 
N= 878 
Titles and abstracts screened 
N=54 
Full-texts articles assess for 
eligibility 
N= 54 
Studies eligible for review 
N=12 !
Additional studies from 
references 
N= 3 
Final Studies selected for 
review 
N=15 
Studies excluded (N=824) 
Reasons: No primary QoL outcome 
761, dementia group only 28, 
intervention 12, biological 9, care 
setting 2, review 2, qualitative 2, 
other population 2, 
neuropsychological 2, other 
language 2 
Studies excluded (N= 42) 
Reasons: Qualitative 8, 
neuropsychological 9, review 5, 
measurement development 5, 
conference and dissertations 4, other 
language 3, dementia group only 4, 
carer population only 2, other 
population 1, intervention 1 
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essential to reduce error by including comparison groups, controlling for potential 
confounding variables and having a large representative sample (Miller, 1998). Thirteen 
studies utilised a comparison group design including a control group and/or a dementia 
group and only one included solely an MCI group (Garand et al, 2007). The studies recruited 
participants from a range of clinical (i.e. memory services, health units) and/or community 
settings (see table 3). Control for confounding variables across the studies was mixed with 
only 3 studies matching control groups on age, gender and education years (Teng et al, 2007; 
Clement et al, 2009; Shin et al, 2012). All studies conducted statistical comparisons between 
demographics variables, however, only 2 out of 4 studies statistically adjusted for variable 
differences when found (Fujiwara et al, 2013; Momtaz, Hamid & Ibrahim, 2013). None of 
the studies specifically accounted for the sample size by describing an appropriate power 
analysis and only 5 studies provided descriptions of non-responders (Fujiwara et al, 2013; 
Momtaz, Hamid & Ibrahim, 2013; St John & Montgomery, 2010; Shin et al, 2012; 
Muangpaisan, Intalapaporn & Assantachai, 2008).  
 
Outcome measures 
The studies included in this review used several different instruments for QoL assessment 
(see table 1). The majority of studies employed self-report measures specifically designed to 
obtain patient ratings of perceived QoL. Five studies used measures that incorporated 
caregiver ratings of QoL (Teng et al, 2012; Barrios et al, 2013; Muangpaisan et al, 2008; 
Maki et al, 2014; Ready et al, 2004; Lapid et al, 2011). None of the scales were specifically 
designed for use with people with MCI but had all been used previously with dementia 
populations. All of the specific QoL measures provided sub ratings of individual QoL 
domains (see Table 1).  
 
Five studies employed validated self-report measures that assessed the individual 
components of QoL i.e. social relationships or psychological well-being (Muangpaisan, 
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Intalapaporn and Assantachai, 2008; Clement et al, 2009; Wettstein et al, 2014; Shin et al, 
2012; St John and Montgomery, 2010; Garand et al, 2007). Only one study used direct self-
report of sexual functioning instead of a validated scale (Momtaz, Hamid & Ibrahim, 2013). 
However, the majority of measures used where not specifically designed for use with older 
people with cognitive impairment. 
 
A variety of standardized measures and neuropsychological tests were also used in all the 
studies to control for confounding variables such as depression, ADLs and cognitive 
function (see table 3).  
 
MCI classification 
There was variation in the methods used to categorise MCI and as a result the criteria used to 
define it. Ten studies employed a range of diagnostic criteria to define MCI that included the 
criterion of presence of an objective impairment, subjective complaint and preserved or 
slight impairment to ADLs (see table 2). Four of the studies used solely neuropsychological 
cut-off scores to define MCI using a range of cognitive assessment tools and cut off 
thresholds (see table 2). Only one study did not describe how the MCI group was 
characterised (Lapid et al, 2011). Four studies made distinctions between MCI subtypes i.e. 
amnestic MCI vs. non-amnestic MCI either focusing on making group comparisons (Garand 
et al, 2007; Fujiwara et al, 2013) or focusing on amnestic MCI  (Barrios et al, 2013; Clement 
et al, 2009; Muangpaisan, Intalaporn & Assantachai, 2008) (see table 2). One study 
compared the modified single domain amnestic to the multiple domains (Clement et al, 
2009). Making a distinction between MCI subtypes may be valuable and offer prognostic 
information, as there is preliminary evidence that amnestic MCI patients may more 
commonly convert to AD (De Carli et al, 2003). 
 
 
 
Table 1: Description of specific QoL measures and sub-components 
QoL Measure Study Components 
!##!
QOL-AD- Quality of Life in Alzheimer’s Disease Scale, SDL- Satisfaction with Daily Life Scale,    
WHOQOL-BREF- WHO Quality of Life-BREF, DQOL- Dementia Quality of Life Scale, ADRQL-  
Alzheimer’s Disease Related Quality of Life, LASA- Linear Analog Scale Assessment 
 
There was also variation in depth of assessment methods used to measure MCI diagnostic 
criteria. Six studies incorporated extensive clinical assessments, neurological and 
neuropsychological assessments (Wettstein et al, 2014; Teng et al, 2012; Clement et al, 
2009; Barrios et al, 2013; Garand et al, 2007; Clement et al, 2009), with one study 
conducting brain imaging (Barrios et al, 2013). Only 7 studies described exclusion criteria, 
which included factors such as depression, substance misuse and other neurological disorder 
QoL-AD Teng et al, 2012 
 
Barrios et al, 2013 
Perceived QoL 
Behavioural competence         
Psychological status  
Interpersonal environment                   
Physical functioning  
 
SDL Maki et al, 2014 Physical function,  
Home life,  
Social life  
Work life  
Personal development/Fulfilment 
Recreation 
Material well-being  
D-QoL Ready et al, 2004 Perceived QoL 
Positive affect                  
Negative affect                 
Feelings of belonging          
Self esteem                
Sense of aesthetics 
ADRQL Missotten et al, 2008 Social Interaction   
Awareness of Self   
Feelings and Mood   
Enjoyment of Activities   
Response to Surroundings    
WHOQOL-BREF Muangpaisan et al, 2008 Physical health            
Psychological health       
Social relationships             
Environmental relationships 
LASA Lapid et al, 2011 Physical well-being 
Emotional state 
Faith 
Religious involvement 
Intellectual state 
Social interactions 
Pain frequency 
Pain intensity  
Coping ability 
!#$!
that may have independently impacted QoL (see Table 2). 
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 Table 2: Descriptions of tools and criteria used in the studies to categorise MCI  
 
 
 
 
 
! Tests MCI criteria MCI subtypes Excluded groups 
Study   Objective 
complaint* 
Subjective 
complaint 
ADL! Definition of MCI MCI AMCI naMCI  
Teng et al, 
2012 
CERAD; IADL ! 
 
! 
 
! 
 
Original Petersen criteria  
 
 
+   Other neurologic disorders, alcohol or substance 
abuse, institutionalised 
Barrios et al, 
2013 
WMS; IADL ! 
 
! 
 
! 
 
European Consortium on AD  +  Alcohol/substance abuse, other 
neurological/psychiatric/medical disorders, major 
depressive episode (>10 on GDS), and education less 
than 4 years 
Maki et al 
2014 
MMSE ! 
 
! 
 
" 
 
International working group 
criteria  
+   Not described 
Missotten et al,  
2008 
MMSE; 
CAMCOG; 
IADL 
! 
 
" 
 
! 
 
Original Petersen criteria  
 
+   Not described 
Ready et al, 
2004  
MMSE; 
CERAD; IADL 
! 
 
! 
 
! 
 
Modified Petersen criteria  
 
+   Other neurologic disorders in past 2 yrs, alcohol or 
substance abuse, institutionalised 
St John & 
Montgomery, 
2010 
3MS; OARS     ! 
 
" 
 
! 
 
3MS < 78 +   Not described 
! "$!
 
 
 
!!" Cognitive impairment generally implies performance >1.5 SD below AEAS on standard cognitive tests                 "!ADLs either intact or slight impairment 
 
CERAD- Consortium to Establish A Registry of Alzheimer’s Disease, IADL- Instrumental Activities of Daily Living Scale, WMS- Wechsler Memory scale, MMSE- Mini   
Mental State Examination, CAMCOG-R- Cambridge Examination for Mental Disorders of the Elderly, 3MS- The Modified Mini-Mental State Test, OARS- Older Americans 
Resources and Services, TMSE- Thai Mini Mental State Examination, HHIES-The Hearing Handicap Inventory for Elderly-Screening, ROILs- Record of Independent Living, 
DRS- Disability Rating Scale,  MOCA- The Montreal Cognitive Assessment, MDRS- Mattis Dementia Rating Scale, SMAF- The Functional Autonomy Measurement System, 
MOCA-J- The Montreal Cognitive Assessment: Japanese Version.
!
Wettstein et al, 
2014 
CERAD 
CAMCOG-R 
! 
 
! 
 
! 
 
International working group 
criteria 
+   Diagnosis of dementia, severe psychiatric disorders, 
sensory deficits affecting mobility, sever somatic 
illness, use of prescription drugs affecting cognition 
Muangpaisan, 
Intalaporn & 
Assantachai, 
2008 
TMSE 
IADL 
! 
 
! 
 
! 
 
Modified Petersen criteria  
 
 +  TMSE < 24, major depression, other psychiatric 
disorders diagnosed with DSM-IV, taking 
psychotropic drugs that affect cognition 
! "#!
Impact on QoL 
 
Perceived QoL  
The review identified 7 studies that directly measured the impact MCI has on perceived QoL 
compared to cognitively healthy controls with 3 studies also incorporating a dementia 
comparison group (see Table 3). The synthesis of the studies yielded mixed findings relating 
to the differences between perceived QoL within MCI compared to cognitively healthy 
controls. Two studies found a decrease in MCI self ratings of perceived QoL compared to 
cognitively healthy controls (Teng et al, 2012; Barrios et al, 2013). However, both studies 
were rated as poor in quality with selected clinical based samples, unjustified sample sizes 
and limited control for confounding variables.  Conversely, five studies found no significant 
differences between MCI self ratings of perceived QoL and cognitively healthy control 
ratings (Muangpaisan et al, 2008; Maki et al, 2014; Ready et al, 2004; Missotten et al, 2008; 
Lapid et al, 2011). The quality of this evidence ranged from poor (Ready et al, 2004; 
Missotten et al, 2008; Lapid et al, 2011) to adequate (Muangpaisan et al, 2008; Maki et al, 
2014). The poorer rated studies included highly unrepresentative clinical samples (i.e. frail 
participants in institutions; Missotten et al, 2008), limited control for other confounding 
factors as well as unjustified and insufficient sample sizes reducing generalisability and 
increasing bias. 
 
Three of these studies also included a dementia comparison group. Two studies found no 
differences between self-rated perceived QoL for MCI and dementia groups (Ready et al, 
2004; Lapid et al, 2011). One study found that MCI participants gave significantly higher 
rating of perceived QoL compared to the dementia group (Missotten et al, 2008). However, 
these studies had variability within the selected samples including exclusively participants 
above 90 years (Lapid et al, 2011), advanced dementia (Missotten et al, 2008) and mild 
dementia (Ready et al, 2004). This may have contributed to the differences in findings. None 
! "$!
of the studies analysed differences in perceived QoL ratings between the different MCI 
subtypes i.e. amnestic vs. non-amnestic MCI.  
 
Psychological Well-being  
Eight studies explored psychological well-being within an MCI population (see Table 3). 
These studies looked at a variety of mood related symptoms including depression, positive 
and negative affect, and anxiety. Four studies employed specific QoL measures with sub-
components assessing aspects of psychological well-being whereas 4 studies used measures 
that assessed specific aspects of psychological well-being exclusively such as a mood scale. 
The study findings have been categorised and evaluated based on the areas of psychological 
well-being assessed. There were a number of studies that assessed multiple aspects of 
psychological well-being and have therefore been discussed separately in each section.  
 
Depression 
Three studies examined depression using specific QoL measures with an associated 
component. Two of the studies found a decrease in MCI self ratings for mood compared to 
cognitively healthy controls using to QoL-AD scale (Teng et al, 2012; Barrios et al, 2013). 
One study found no significant difference between MCI participants and cognitively healthy 
controls on the feelings/mood component of the ADRQL (Missotten et al, 2008). However, 
all 3 of these studies were rated as poor in quality due to unrepresentative and unjustified 
sample sizes as well as limited control for confounding variables.  
 
Using independent measures of depression, Shin et al (2012) found adequate quality 
evidence that depression levels did not significantly differ between the MCI participants and 
cognitively healthy controls that were matched on age, gender, education and IADLs. 
Strengths of this study included use of a validated measure of depression designed for a 
geriatric population (GDS) as well as a large, community based sample and controlling for a 
! "%!
large variety of socio-demographic factors. Muangpaisan, Intalapaporn and Assantachai 
(2008) also found adequate evidence that MCI participants did not differ significantly in 
depression subscale scores using a neuropsychiatric symptom scale. However, the study only 
controlled for a limited number of confounding factors (i.e. age) and had uneven sample 
sizes across the two groups thus reducing the validity of finding. 
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               Table 3: Descriptions of studies exploring QoL in MCI 
Study Study 
quality 
N Sample        Informant 
ratings? 
Age and 
education 
controlled 
QoL Scale  Analysis Results-  
QoL Components 
Teng et al 
2012 
3 MCI  
Memory service 
 
 
Aged/education 
matched Controls  
Community 
 
 
 
USA 
Age (yrs) 
 
 
Gender (%males) 
 
 
Education Level (yrs) 
 
        !+ 
 
! ** 
QoL-AD 
 
Administration not 
described. 
T-tests 
Effect sizes 
Correlations 
! 
Perceived QoL 
 
! 
Mood 
 
! 
Memory  
 
 
 
Barrios et al 
2013 
3 MCI  
Memory service 
 
 
Healthy controls  
Medical Outpatient 
center 
 
 
Portugal  
Age (yrs) 
 
 
Gender (%males) 
 
 
Education Level (yrs) 
 
       !" 
 
" 
 
** 
QoL-AD 
 
Administration by 
interviewer 
T-tests ANOVAs ! 
Perceived QoL 
 
! 
Social Environment  
 
! 
Mood 
 
 
*Validated   *Validated measure            + Concordance in MCI self & informant & QoL ratings      ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI     " No concordance in MCI self & informant QoL ratings     " No significant differences in MCI & control ratings (p<0.05) 
                         ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                               " No significant differences in MCI & dementia ratings (p<0.05) 
                                                                                                                                              
! !
! $%!
Maki et al 
2014 
6 MCI  
Community 
 
 
Healthy controls 
Community 
 
 
 
Japan 
Age (yrs) 
 
 
Gender (%males)* 
 
 
Education Level (yrs) 
 
" 
 
! 
&  
depression, 
memory 
complaints, 
self-
efficacy, 
social 
environme
nt 
 
** 
SDL 
 
Administration by 
interviewer. 
T-tests 
Correlations 
Regression  
  
" 
Perceived QoL 
 
Missotten et 
al,  
2008 
3 MCI  
Home or residential 
care 
 
Frail elderly  
Home or residential 
care 
 
 
Dementia  
Home or residential 
care 
 
 
Belgium  
 
Age (yrs) 
 
 
Gender (%males)* 
 
 
Education Level (yrs) 
 
! 
 
 
" 
 
** 
ADRQL 
 
Administer by 
interviewer.  
 
 
 
T-test 
ANOVA  
Post hoc tests 
"! 
Perceived QoL 
 
! 
Social interaction  
 
! 
Mood  
 
! 
Enjoyment of 
activities 
 
! 
Awareness of Self 
 
! 
Response to 
activities  
Validated   *Validated measure            + Concordance in MCI self & informant & QoL ratings       ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI   " No concordance in MCI self & informant QoL ratings       " No significant differences in MCI & control ratings (p<0.05) 
                         ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                               " No significant differences in MCI & dementia ratings (p<0.05) ! !
! $&!
Ready et al 
2004  
 
 
   DQoL Correlations 
ANOVAs  
No 
sign
ifica
nt 
diff
eren
cesb
etw
een 
gro
ups 
No 
significant 
differences 
 
, 
 
 
3 
 
 
 
 
MCI 
Memory Service 
   
Elderly Controls 
Community 
 
 
AD 
Memory Service 
 
 
 
USA 
Age (yrs) 
 
 
Gender (%males) 
 
 
Education Level (yrs) 
 
 
       !+ 
 
 
" 
 
** 
DQOL 
 
Administration by 
interviewer 
(neuropsychologists
) 
 "" 
Perceived QoL 
 
! 
Self esteem 
 
 
Muangpaisan 
et al 
2008 
5 MCI 
Community  
 
 
Healthy Controls 
Community 
  
 
 
 
Thailand  
Age (yrs) 
 
 
Gender (%males) 
 
 
Education Level (yrs) 
 
" 
 
 
! 
 
 
 
 
 
 
 
 
 
 
 
** 
WHOQOL-BREF 
 
Administration not 
described.  
T-test  
Fisher exact 
ANOVA   
Correlations  
" 
 
Perceived QoL 
 
! 
Psychological 
 
 
*Validated *Validated measure                              + Concordance in MCI self & informant & QoL ratings      ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI                     " No concordance in MCI self & informant QoL ratings     " No significant differences in MCI & control ratings (p<0.05) 
                                          ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                                                " No significant differences in MCI & dementia ratings (p<0.05) ! !
! $"!
Lapid et al, 
2011 
3 MCI 
Community  
 
 
 
Healthy Controls 
Community  
 
 
Dementia 
Community 
 
 
DEMSP 
Community  
 
 
USA 
Age  
 
 
Gender (%males) 
 
 
Education Level (yrs) 
 
!+ " 
 
** 
LASA 
 
Self-completed 
Fisher exact  
Correlations 
 
"" 
Perceived QoL 
 
!! 
Physical well-being 
 
!! 
Intellectual Well-
being 
 
!! 
Pain frequency 
 
!! 
coping with stress 
ability 
  
Shin et al, 
2012 
5 MCI 
Community Health 
Unit 
 
 
Controls 
Community Health 
Unit 
 
Korea 
Age 
 
 
Gender 
 
 
Education Level 
 
N/A !  
Matched 
controls 
& 
IADLs 
** 
GDS 
 
T-tests 
Regression 
 
! 
Depression 
Validated   *Validated measure            + Concordance in MCI self & informant & QoL ratings      ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI   " No concordance in MCI self & informant QoL ratings      " No significant differences in MCI & control ratings (p<0.05) 
                         ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                               " No significant differences in MCI & dementia ratings (p<0.05) ! !
! $$!
Clement et al, 
2009 
4 MCI 
Memory service  
 
 
Controls 
Community  
 
 
France 
 
Descriptive statistics not 
described. 
 
 
N/A !  
Matched 
controls 
& 
social 
functioning
, physical 
health  
 
** 
PSI 
 
 
PGC-S 
 
ANOVAs 
ANCOVAs 
MANCOVAs 
Correlations 
 
 
! 
Depression 
 
! 
Morale 
 
! 
Anxiety 
 
! 
Hostility 
Wettstein et 
al, 2014 
3 MCI 
Memory clinic 
 
 
Controls 
Community 
 
 
AD 
Memory clinic 
 
 
Germany and Israel 
Age 
 
 
Gender 
 
 
Education Level 
 
 
 
 
 
 
N/A 
 
 
!  
(education 
only) 
& 
country  
 
** 
GDS 
 
** 
PANAS 
 
ANCOVA 
MANCOVA 
Effect sizes 
 
!! 
Positive affect 
 
! 
Negative affect 
Validated   *Validated measure            + Concordance in MCI self & informant & QoL ratings      ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI   " No concordance in MCI self & informant QoL ratings      " No significant differences in MCI & control ratings (p<0.05) 
                         ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                               " No significant differences in MCI & dementia ratings (p<0.05) 
 
! !
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Fujiwara et al, 
2013 
6 MCI 
Community 
 
 
Controls 
Community 
 
 
 
 
 
Japan 
Age 
 
 
Gender 
 
 
Education Level 
 
 
 
N/A ! 
& 
gender 
 
 Self rated Chi-square 
Fisher Exact 
Regression 
! 
 Depression 
Muangpaisan, 
Intalapaporn 
and 
Assantachai, 
2008 
5 MCI 
Community health 
unit 
 
 
Controls 
Community health 
unit 
 
 
Thailand 
Age 
  
 
Gender 
 
 
Education Level 
 
 
 
 
N/A " 
 
** 
NPI 
T-tests 
Fisher exacts 
Chi Square 
Regression 
! 
Anxiety 
 
! 
Apathy 
 
! 
Dsyphoria 
Validated   *Validated measure            + Concordance in MCI self & informant & QoL ratings      ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI   " No concordance in MCI self & informant QoL ratings      " No significant differences in MCI & control ratings (p<0.05) 
                         ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                               " No significant differences in MCI & dementia ratings (p<0.05) 
 
 
St John & 5 MCI  Age (yrs) " ! * T-test  ! 
Social LS 
! !
! $(!
Montgomery, 
2010 
Community 
 
 
Healthy controls  
Community 
 
 
Dementia 
Community 
 
 
 
Canada 
 
 
Gender (%males)* 
 
 
Education Level (yrs)* 
 
 
 &  
depression 
gender 
functional 
impairment 
TDS 
 
Administered by 
interviewer.  
 
ANOVA  
Garand et al, 
2007 
4 MCI 
Research centre 
 
 
 
 
 
USA 
 
 
 
 
 
 
Age (yrs) 
 
 
Gender (%males)* 
 
 
Education Level (yrs)* 
 
 
 
 
 
 
" 
 
! 
 & 
caregiver 
distress 
 
* 
DAS 
Correlations 
Regression 
Marital Quality  
(see table 3) 
 
Validated   *Validated measure            + Concordance in MCI self & informant & QoL ratings      ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI   " No concordance in MCI self & informant QoL ratings      " No significant differences in MCI & control ratings (p<0.05) 
                         ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                               " No significant differences in MCI & dementia ratings (p<0.05) 
Momtaz et al, 
2013 
6 MCI  
Community  
Descriptive statistics not 
described for each group. 
" ! 
& 
Self report Regressions ! 
Sexual activity 
! !
! $)!
 
 
Controls 
Community  
 
 
 
 
Malaysia 
 
Age (yrs) 
 
 
Gender (%males)* 
 
 
Education Level (yrs)* 
 
 
 Gender 
Medical 
conditions 
 
                 *Validated measure                  + Concordance in MCI self & informant & QoL ratings       ! Significant differences in MCI & control ratings (p<0.05) 
                *Previously used in MCI          " No concordance in MCI self & informant QoL ratings      " No significant differences in MCI & control ratings (p<0.05) 
                               ! Significant differences in MCI & dementia ratings (p<0.05) 
Poor quality Adequate quality                                                                     " No significant differences in MCI & dementia ratings (p<0.05) 
                                                                                                                                                                                                       
DAS- dynamic adjustment scale; TDS- Terrible Delightful Scale, NPI- Neuropsychiatric Inventory, PANAS- Positive and Negative Affect Scale, GDS- Geriatric Depression, 
PSI- Psychiatric Symptom Index, PGC-MS- revised Philadelphia Geriatric Center Morale Scale, LASA- Linear Analog Scale Assessment, WHOQOL-BREF- WHO Quality of 
Life-BREF, DQOL-  Dementia Quality of Life Scale, ADRQL- Alzheimer’s Disease Related Quality of LIfe  , SDL- Satisfaction with Daily Life Scale, QOL-AD- Quality of 
Life in Alzheimer’s Disease Scale  
! !
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Another study found an increase in depressive symptoms for MCI participants compared to 
cognitively healthy controls but with small effect sizes (Wettistein et al, 2014). There were no 
differences in depression levels between MCI and AD participants. However, the quality of the 
findings were rated as poor due to selection and comparability issues. This study also included a 
longitudinal analysis finding that depression declined over time in MCI participants and 
cognitively healthy controls but increased in AD participants. However, these finding must be 
interpreted with significant caution due to very small sample sizes. Conversely, another study 
found more adequate evidence that MCI participants had significantly higher levels of depression 
compared to cognitively healthy controls (Clement et al, 2009). However, it is important to note 
that this study was conducted in a clinical setting making it less representative and conducted a 
high number of statistical comparisons that may have introduced error.  
 
Positive and negative affect 
Two studies looked specifically at positive and negative affect, with one study using a general 
QoL measure with an associated sub-component (Ready et al, 2004) and the other using a specific 
affect scale (Wettstein et al, 2014). The studies found conflicting evidence, however, both were 
rated poor in quality due to lack of control for confounding variables, clinical samples and 
significant differences in demographics across the groups. Ready et al (2004) found no significant 
differences between MCI participants and cognitively healthy control ratings of positive and 
negative affect using DQOL. Wettstein et al (2014) found that MCI participants reported less 
positive affect than cognitively healthy controls but these group differences were of small effect 
sizes. Furthermore, Wettstein and colleagues included a dementia comparison group but found no 
differences across the two groups in affect. A longitudinal analysis found that positive affect 
increased for all groups over time but that negative affect increased in the MCI group only. 
However, these longitudinal findings must be interpreted with significant caution due to a small 
sample size. Two further studies explored specific negative and positive affect symptoms, and 
found adequate evidence for higher anxiety, dsyphoria, hostility and irritability (Muangpaisan, 
! "$!
Intalapaporn & Assantachai, 2008; Clement et al, 2009) and lower morale (Clement, 2009) in 
MCI participants compared with elderly controls.   
 
Four studies also looked at enjoyment of life, a specific aspect of positive affect, using a variety 
of measures (Barrios et al, 2004; St John & Montgomery, 2010; Missotten et al, 2008; Ready et 
al; 2004) (see Table 3). Barrios et al (2013) found decreases in MCI reports on the ability to enjoy 
themselves component of the QoL-AD scale. Two further studies found no significant differences 
between MCI participants and controls on the life enjoyment components of ADRQL (Missotten 
et al, 2008) and D-QOL; Ready et al, 2004). St John and Montgomery (2010) found that MCI 
participants rated significantly lower satisfaction with life than controls. The quality of this study 
was adequate but had significant weakness due to measure selection and discrepancies in 
demographics and sizes of the group samples. Two studies also included a comparison with a 
dementia group with both finding no significant differences in life enjoyment between MCI and 
people with dementia (St John & Montgomery, 2010) and AD (Ready et al, 2004). 
 
Social relationships 
Seven studies investigated different aspects of social functioning and how they are affected in 
MCI participants compared to cognitively healthy controls and/or dementia participants (see 
Table 3). Most of the studies used a range of validated self-report measures, which either 
measured QoL with a social component or measured a specific aspect of social relationships. St 
John and Montgomery (2010) found poor quality evidence that social satisfaction was lower in 
MCI participants than cognitively healthy controls but with no significant differences between 
MCI and AD participants. However, this study did not control for significant demographic 
discrepancies between the groups and used a measure not validated with an older adult 
population. Barrios et al (2013) also found that MCI participants reported a decrease in the 
quality of social relationships using the QoL-AD but was considered poor evidence due to issues 
with sample selection and comparability of the data.  
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Two further studies also using the QoL-AD found no significant differences between MCI 
participants and cognitively healthy controls on the social relationship domain (Teng et al, 2012; 
Muangpaisan et al, 2008). Two other studies also found no significant differences on the social 
interaction component of ADRQL (Missotten et al, 2008) and social life component of SDL 
(Maki et al, 2014). 
 
The quality of these studies ranged from poor (Teng et al, 2012; Missotten et al, 2008) to 
adequate (Muangpaisan et al, 2008; Maki et al, 2014). The higher quality studies used a more 
representative sample from the community compared to clinical services used in the other two 
studies and therefore can be perceived as more generalisable.  
 
Two studies looked specifically at aspects of social relationships that are impacted by MCI; 
marital quality (Garrand et al, 2007) and sexual activity (Momtaz, Hamid & Ibrahim, 2013). 
Garrand et al (2007) found that lower marital satisfaction was significantly related to MCI-related 
behaviours such as repeated questioning, remembering recent events, less communication and 
anger. However, the lack of a comparison group and an unrepresentative sample of educated, 
Caucasian women from a clinical population meant the study only provided adequate evidence. 
Momtaz, Hamid & Ibrahim (2013) found that people with MCI were less likely to have sex than 
cognitive healthy controls. However, these finding are poor in quality due to lack of confound 
control and weak outcome measurement i.e. self-report.   
 
Other QoL components 
Seven studies using specifically designed QoL measurements also assessed other components 
related to QoL (see Table 3). Only four studies found significant differences between MCI 
participants, cognitively healthy controls and/or dementia on particular components. In 
comparison to cognitively normal controls two studies found reduced memory in MCI 
participants (Teng et al, 2012; Barrios et al; 2013). Another study found MCI participants 
endorsed better physical and intellectual well-being, pain frequency and ability to cope with stress 
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in comparison to cognitively healthy controls and dementia participants (Lapid et al, 2011). 
Furthermore, significant differences were found between MCI and dementia participants on other 
components of QoL including response to activities, awareness of self (Missotten et al, 2008) and 
self-esteem (Ready et al, 2004). However, it is worth emphasising that all of these studies were 
rated as poor in quality with weaknesses that impact both the validity and reliability of the 
findings. No significant differences were found on components relating to physical health and 
functioning, the behavioural component, home and work life, recreation, material well-being, 
personal fulfilment or environmental relationships.  
 
Informant vs. self QoL ratings 
Five studies used measures that also incorporated informant perspectives of perceived QoL 
(Ready et al, 2004; Teng et al, 2012; Barrios et al, 2013; Lapid et al, 2011) but one study did not 
analyse informant data (Missotten et al, 2008). All 4 studies explored concordance between self 
and informant ratings of perceived QoL within each group (i.e. MCI, dementia, control). Two 
studies found significant agreement between MCI informants and self ratings of perceived QoL 
(Ready et al, 2004; Lapid et al, 2011). One study found a positive correlation between perceived 
QoL ratings but this did not reach statistical significance and no differences were found between 
the mean perceived QoL scores (Teng et al, 2012). Furthermore, there were no differences found 
between amnestic MCI and non-amnestic MCI informant ratings of perceived QoL (Teng et al, 
2012). A third study found that MCI participants rated perceived QoL significantly more 
favourably than informants (Barrios et al, 2013). On analysing informant and self ratings on 
individual QoL components one study found that MCI participants were more favourable than 
their informants on ratings of family, ability to do house chores, self as a whole & life as a whole.  
 
Three studies also compared MCI informant ratings against the informant comparison groups i.e. 
control or dementia. Two studies found that MCI informants reported significantly lower 
perceived QoL compared to cognitively healthy control informants (Teng et al, 2012; Barrios et 
al, 2013).  More specifically, one study also found significant impairment on informant ratings 
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for specific QoL sub-components informants such as mood, ability to enjoy activities, life as a 
whole and memory (Teng et al, 2012). Conversely, one study found no differences between the 
MCI and cognitively healthy control informant ratings of perceived QoL or individual QoL 
components (Ready et al, 2004). However, the authors found that AD informants reported 
significantly lower perceived QoL and self esteem than MCI informants. Only one study explored 
potential predictors of informant ratings of perceived QoL and found that reduced QoL was 
associated with decreased functional abilities, higher levels of depression and greater 
neuropsychiatric symptoms (Teng et al, 2012).  However, it is important to note that all 4 studies 
had significant weaknesses in their design that affects the quality of these findings and reduces 
the inferences that can be drawn.   
 
Predictors of QoL  
A number of the studies investigated factors that determine the impact of MCI on perceived QoL 
and specific QoL components. Five studies explored a variety of factors that influence perceived 
QoL and could be considered potential predictors (see Table 4; Teng et al, 2012; Maki et al, 
2013; Muangpaisan et al, 2008; Barrios et al, 2013; Lapid et al, 2011). Four studies found higher 
levels of depression were associated with reductions in QoL for MCI participants using the GDS 
and these correlations were categorised as strong (Teng et al, 2012; Maki et al, 2013; 
Muangpaisan et al, 2008; Barrios et al, 2013). Furthermore, using regression analysis two studies 
found depression to be a significant negative predictor of perceived QoL after controlling for 
other demographic and cognitive factors (Maki et al, 2013; Barrios et al, 2012). Additionally, 
Maki et al (2014) found that greater memory complaints, reduced self-efficacy and poorer social 
environment were also strongly associated with a decrease in perceived QoL for MCI 
participants. Furthermore, QoL was found to be predicted positively by self-efficacy after 
controlling for depression and social environment in a regression analysis. They also found that 
more impaired ADLs and increased age was associated with lower perceived QoL for MCI 
participants, however, these correlations were much weaker. Surprisingly, only one study 
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demonstrated a strong association between cognitive function and perceived QoL (Lapid et al, 
2011).  
 
Three studies explored possible predictors of psychological well-being (Muangpaisan et al, 2008; 
Clement et al, 2009) Muangpaisan et al (2008) found a strong negative correlation between 
depression scores on the GDS and NPI depression subscale i.e. higher level of depression was 
associated with decrease in QoL for MCI participants. Clement et al (2009) found that 
psychological health decreased with increased cognitive impairment after controlling for age and 
was classified as a moderate correlation. In relation to positive affect, St John and Montgomery 
(2010) found that lower cognition resulted in lower life satisfaction for each group and remained 
consistent after controlling for age, education, depression and functional impairment in a linear 
regression model. Across all the groups higher life satisfaction was most strongly predicted by 
less depressive symptoms and less impaired functional status. Higher education and higher 
income security were also predictive of higher life satisfaction but to a lesser extent.  
 
Two studies also explored predictors of quality of social relationships (St John & Montgomery, 
2010; Garand et al, 2007). Using a linear regression model, St John and Montgomery (2010) 
found that higher social satisfaction was predicted by gender, higher education, more income 
security, fewer depressive symptoms, less disability and less impaired cognition. Specifically 
exploring quality of marital relations, Garand et al (2007) found that higher marital quality was 
strongly associated with a number of MCI related behaviours (i.e. anger, dependency, memory 
impairment). However, after controlling for age and caregiver stress using a linear regression 
limited communication remained the only significant predictor of marital satisfaction, cohesion 
and affective expression whereas repetitive questioning predicted marital satisfaction onl
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Table 4: Correlations between potential predictors of QoL and the different QoL components  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Controlled for SE    * Controlled for depression    *Controlled for memory complaint   X = no significant correlation mean  
!!= Strong negative correlation!!!!!! = Moderate negative correlation!!!!!!= Weak negative correlation           poor !!!!!!!!!!!!!!!!!!!!!!! 
!!"= Strong positive correlation       "= Moderate positive correlation      "= Weak positive correlation adequate  
!
!
Perceived QoL  
Study Study 
Quality 
Depression Memory 
Complaint 
IADL 
 
Age Social 
environment 
Self efficacy Cognitive 
function 
Education Income Gender MCI specific 
behaviour  
Teng et al, 2012 3 !   X X 
 
  
 
X X    
Maki et al, 2014 6 !!!** !** "  ! "  !!" ** X     
Muangpaisan et al, 
2008 5 !    X  X     
Lapid et al, 2011 
 
3 X      !     
Psychological wellbeing 
Study Study 
Quality 
Depression Memory 
Complaint 
IADL 
 
Age Social 
environment 
Self efficacy Cognitive 
function 
Education  Income Gender MCI specific 
behaviour  
Clement et al, 2009 4       !*     
Muangpaisan et al, 
2008 
5 !      X     
Social relationships 
Study Study 
Quality 
Depression Memory 
Complaint 
IADL 
 
Age Social 
environment 
Self efficacy Cognitive 
function 
Education  Income Gender MCI specific 
behaviour  
St John and 
Montogomery, 
2010 
5 !  !    "  "  "  "   
Garand et al, 2007 4           "  
Life enjoyment 
Study Study 
Quality 
Depression Memory 
Complaint 
IADL 
 
Age Social 
environment 
Self efficacy Cognitive 
function 
Education  Income Gender MCI specific 
behaviour  
St John and 
Montogomery, 
2010 
5   ! X   "  "     
!
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DISCUSSION 
 
Summary of findings  
This review evaluated studies exploring QoL within an MCI population that took place across 
different countries and employed a range of specifically designed QoL measures. All of the 
studies are cross-sectional in design and recruited samples from many settings i.e. clinical 
memory services to community dwellers. A range of diagnostic criteria has also been used to 
define MCI. The main findings from the review have been summarised below.  
 
Impact on perceived QoL 
The evidence regarding the impact of MCI on patients’ self-perceived QoL is inconclusive due 
to a lack of good quality studies. The majority of the evidence indicated that people with MCI 
do not view their QoL as affected compared to those without cognitive impairment or dementia 
(Muangpaisan et al, 2008; Maki et al, 2014; Ready et al, 2004; Missotten et al, 2008; Lapid et 
al, 2011). Only poor quality evidence demonstrated a reduction in perceived QoL for people 
with MCI compared to those who are cognitively healthy or those with dementia (Teng et al, 
2012; Barrios et al, 2013). These findings were somewhat surprising given findings obtained in 
other reviews that MCI presents a number of emotional and practical challenges (Dean & 
Wilcock, 2012). However, heterogeneity across the sample populations (i.e. from community 
dwellers to frail institionalised elderly) along with unjustified sample sizes make comparisons 
across the studies difficult thus limiting conclusions drawn and may have contributed to the 
conflicting findings. 
 
Impact on psychological well-being   
Attempts to define the core components that comprise QoL are in agreement that conceptually 
psychological well-being plays an essential role (Lawton et al, 1991). The studies explored a 
variety of aspects of psychological well-being i.e. depression, positive affect and negative affect 
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but in general yielded inconsistent and poor quality findings. There was adequate evidence that 
depression was higher in MCI participants compared with cognitively healthy controls (Teng et 
al, 2012; Barrios et al, 2013; Wettistein et al, 2014; Clement et al, 2009). However, the studies 
included clinical samples where baseline of depression or distress relating to cognitive 
symptoms maybe higher illustrated in the need to seek out support services. Evidence from 
community-based studies indicated no difference in depression and was deemed adequate in 
quality (Shin et al, 2012; Muangpaisan, Intalapaporn & Assantachai, 2008). There was also 
somewhat adequate evidence for higher levels of anxiety, dsyphoria, hostility irritability and 
lower morale in MCI population (Clement et al, 2009; Muangpaisan, Intalapaporn & 
Assantachai, 2008). Evidence exploring differences between MCI and dementia patients in 
aspects of psychological well-being was limited and poor in quality thus not making it possible 
to draw conclusions.   
 
Impact on social relationships 
Another important component of QoL indicated by previous studies is the quality of social 
relationships (Lawton, 1991). The review again yielded conflicting findings across studies 
regarding the impact MCI has on social relationships. Most evidence demonstrated a decrease in 
social satisfaction (St John & Montgomery, 2010) and relationships (Muangpaisan et al, 2008; 
Teng et al, 2012; Missotten et al, 2008) compared to cognitively healthy controls. However, this 
evidence was poor with limited control for confounding variables and use of clinically 
unrepresentative samples. More consistent evidence indicated that MCI might present an issue 
within spousal relationships with reduction in marital quality related to MCI specific behaviours 
(Garand et al, 2007) and a reduction in sexual activity (Momtaz, Hamid & Ibrahim, 2013). 
Evidence comparing MCI and dementia was limited and poor in quality thus no firm conclusion 
can be drawn.  
 
Impact on other QoL components 
The review provided evidence for other areas of QoL that appeared to be impacted by MCI 
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including memory (Teng et al, 2012; Barrios et al, 2013), self-esteem (Ready et al, 2008), 
awareness and responsive to environment (Missotten et al, 2008), physical and intellectual well-
being, experiences of pain and ability to cope with stress (Lapid et al, 2011) compared to people 
with healthy cognition and/or different types of dementia. No studies were identified that 
specifically investigated these components with independent methods and this evidence was 
deemed poor in quality with poor validity and reliability thus firm conclusions could not be 
drawn.  
 
Informant ratings  
There was poor and inconsistent evidence regarding the concordance with MCI participants and 
their informants QoL report making it not possible to draw conclusions (Teng et al, 2012; 
Barrios et al, 2013). The evidence comparing MCI and cognitively healthy informants was more 
consistent with the majority of studies demonstrating less favourable reports of perceived QoL, 
mood, life enjoyment and memory for MCI informants (Teng et al, 2012; Barrios et al, 2013). 
However, poor methodological issues (see below) greatly reduced the validity and reliability of 
these findings and firm conclusions could not be drawn.  There was limited evidence comparing 
with dementia informants with only one study indicating better perceived QoL and self-esteem 
for MCI informants (Ready et al, 2004).  
 
Predictors of QoL 
There was consistent evidence indicating depression as a significantly strong predictor of 
reduced perceived QoL, psychological well-being and social relationships in MCI (Barrios et al, 
2013; Teng et al, 2012; Maki et al, 2013; Muangpaisan et al, 2008; St John & Montgomery, 
2010; Clement et al, 2009; Garand et al, 2007). Memory complaints, self-efficacy, social 
environment and cognitive functioning also strongly predicted MCI impact on perceived QoL 
(Maki et al, 2013; Lapid et al, 2011). There was good evidence of level of cognitive impairment 
as a predictor of psychological well-being and social relationships (Muangpaisan et al, 2008; 
Clement et al, 2009; St John & Montgomery, 2010). Meanwhile, there was weaker evidence for 
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gender, age, education, income security, disability and MCI specific behaviours as predictors of 
the impact MCI has on different components of QoLs but most commonly marital relationships 
(Garand et al, 2007).   
 
Methodological and conceptual l issues 
A number of methodological issues across the studies limit the conclusions that can be made 
from this review. Firstly, the cross-sectional nature of all studies does not permit causal 
inferences to be drawn from any of the findings. Longitudinal studies are required before firm 
conclusions can be drawn from the evidence regarding MCI and QoL. Secondly, comparability 
was an issue for many of the studies due to lack of controls for confounding variables (i.e. 
physical health) and a minimal number of studies using exclusion criteria. This is essential in 
cross sectional studies to reduce overestimates or underestimates of the true effect of a disease 
on an outcome. For example, a number of the studies excluded people with psychiatric disorder 
that may have influenced the impact on psychological well-being. Thirdly, the participants were 
recruited from a mixture of clinical services or community dwellers, which poses a challenge 
when comparing the findings, and introduces selection bias. Furthermore, the findings from the 
clinical samples cannot be generalized to the general population of cognitively impaired adults. 
Fourthly, all of the studies failed to describe a power analysis in the methods and therefore it is 
unknown whether the samples are powered correctly. Cross sectional studies require a high 
sample size to be adequately powered and therefore it can be assumed that some of these studies 
may be underpowered increasing the risk of a Type 2 error (Dos Santos Silva, 1999). Other 
frequent problems that occurred in the reviewed studies included significant discrepancies in the 
sample sizes across the groups, limited description of non-responders and ascertainment of 
exposure to risk that may have introduced further error and bias in the findings. These 
methodological issues across the studies may account for many of the inconsistent and 
conflicting findings found in this review. 
 
There were also a number of conceptual issues that posed a problem at this review and may 
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have further contributed to the inconsistent results. Firstly, the studies took place across a 
number of different countries that have varying cultural practices in care for the elderly. For 
example, Asian cultures have a tendency for family focused care where western cultures tend 
focus on independence and indivdidualised care (Bengston et al, 2000). This may influence the 
extent to which QoL is impacted by MCI thus reducing the comparably of the studies findings 
and applicability to the UK.  
 
Secondly, the majority of the measures used in the studies involved participants rating their own 
QoL enabling the possibility of capturing aspects of dementia only available to patients and 
therefore improve the measurement of therapeutic intervention effects (Frank et al, 2011). 
However, researchers have raised concerns about using patient report measures in cognitive 
impairment due to impairments and loss of insight interfering with accurate completion 
reducing the reliability and validity of study findings (Frank et al, 2011). They therefore 
emphase a need to incorporate informant and clinician report (Vogel et al, 2004; Farias et al, 
2005). In this review, a number of studies used measures that also incorporated an informant 
perspective to gain a more reliable estimate of QoL and reduce bias within the findings. 
Additionally, these studies analysed agreement within these further increasing reliability. 
However, there are concerns also with the accuracy of informant reports, especially family 
caregivers, due to biases introduced by caregiver depression and lack of awareness of some 
symptoms (Arguelles et al, 2001). It would have therefore be helpful to include objective 
measures of QoL, however, none of studies in this review did this. Furthermore, none of the 
measures had been specifically designed for use with an MCI population and therefore may 
reduced the generalisability of the findings.  
 
A third conceptual issue was the range of diagnostic criteria used to categorise MCI across the 
studies (see Table 2) that undoubtedly impacts the extent to which an MCI cohort is cognitively 
impaired. For example, studies using MOCA cut off scores of less than 26 will have a less 
cognitively impaired sample than studies using scores less than 23. This may affect the impact 
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MCI has on QoL inline with evidence that differences in criteria used to define MCI results in 
differing estimates of prevalence, incidence and conversion rates (Bischkop et al, 2002; Ritchie 
et al, 2001; Kumar et al, 2005). Additionally, the majority of studies failed to separate the MCI 
groups into the specific subtypes despite research demonstrating different possible outcomes 
associated with amnestic MCI and non-amnestic MCI (Petersen et al, 2014). 
 
Furthermore, a fourth related conceptual issue adding to the heterogeneity across the samples is 
the varying stringency of exclusion criteria used across the studies. There were some studies 
that excluded participants based on a variety of factors that might have reduced cognitive 
functioning (e.g. psychotropic drugs) whilst other studies did not describe exclusion at all. This 
may have further impacted the amount to which the cohorts were cognitively impaired. It is 
plausible to assume that the varying exclusion criteria and lack of attention given to MCI 
subtypes will have resulted in more heterogeneity across the MCI groups that may have 
contributed to the inconsistent and conflicting findings. 
 
Implications for future research and clinical practice 
This review has found somewhat inconsistent evidence for the impact a diagnosis of MCI has 
on QoL. With a national priority for early diagnosis and treatment of dementia (Prince et al, 
2011) the rates of referral for assessment and, hence, diagnosis of MCI is expected to increase 
in the UK in the coming years (Dean & Wilcock, 2012). The findings from this review, however 
inconsistent, have demonstrated some reduction across a variety of aspects of QoL that warrant 
further exploration. Further longitudinal research is needed on a large community scale that is 
adequately powered to yield high quality evidence concerning QoL in MCI. Previous reviews 
have demonstrated the negative impact a diagnosis of MCI has on emotional and practical lives 
of the person and those who care for them (Dean and Wilcock, 2012). A clearer understanding 
of how a diagnosis of MCI impacts QoL directly will enable the development of appropriate 
psychosocial interventions to best support the needs of this population, in line with the UK 
dementia strategy (Logsdon, McCurry & Teri, 2007). Furthermore, in order to fully understand 
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the impact on QoL, future research will need to combine qualitative work alongside use of 
objective and subjective measures, and find innovative ways of combining quantitative and 
qualitative findings (Lewin, Glenton, & Oxman, 2009). 
 
A plausible explanation for some of the inconsistencies currently found within the literature is 
the shortage of specific outcome measures designed to assess QoL in an MCI population. The 
measures used in the majority of studies were designed to measure QoL or aspects of this within 
an older adult or dementia population and therefore may not be applicable to MCI were the 
cognitive and behavioural symptoms differ. There has been some research attempting to 
validate QoL measures within an MCI population (Tatsumi et al, 2011) but with an increasing 
emphasis on symptoms, correlates, and impact of MCI research should focus on the 
development of new MCI specific QoL measures. This would enable more in depth 
understanding of the impact and thus aid the development of clinical interventions to maximize 
this accordingly. However, before measures can be developed a more coherent definition of 
QoL in MCI is needed to aid future research. Past research has also highlighted the importance 
of incorporating the informant when assessing QoL in this population due to potentially limited 
insight arising from cognitive impairment (Whitehouse, 1999; Frank et al, 2011). In the current 
review only a limited amount of studies incorporated informant ratings of QoL from a close 
relative, mainly spousal partner, and the evidence regarding concordance in rating was 
conflicting (Ready et al, 2004; Teng et al, 2012; Barrios et al, 2013; Missotten et al, 2008; Lapid 
et al, 2011). It would therefore be beneficial to investigate this further using an objective 
measure of QoL as well as subjective ratings using newly designed measures to incorporate this 
perspective.   
 
There was consistent evidence in the review regarding the negative impact MCI diagnosis has 
on social relationships and more specifically spousal relations. Authors developing interventions 
to maximise QoL for people with MCI should consult the literature on spousal relationships and 
MCI from both perspectives to understand how best to develop services to support these 
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relationships. Furthermore, there was also consistent evidence provided in this review regarding 
the predictive impact of level of depression on reducing QoL in MCI. This is in line with a 
significant amount of research that demonstrates QoL is intrinsically associated with low mood 
(Jugwirth et al, 2004; Pearman & Storandt, 2004; Wang et al, 2004). These findings 
demonstrate the need to integrate depression scales into assessment procedures to ascertain 
those at higher risk of QoL reduction following an MCI diagnosis. This would then enable 
interventions to reduce depression to be targeted early and potentially maximize QoL for these 
people and their support networks. However, these cross-sectional correlates may differ from 
predictors of QoL and therefore the data needs to be replicated within a longitudinal design 
before being interpreted with confidence (Ready et al, 2004). Meanwhile, researchers choosing 
to continue to investigate QoL within MCI need to firstly consider the issues of MCI diagnostic 
criteria and the wide variety currently used within the research field.  
 
Conclusion 
The current evidence exploring how QoL is affected within an MCI population lacks good 
quality studies and has yielded conflicting findings. No firm conclusions can be drawn due to a 
number of methodological and conceptual limitations. The inconsistencies in findings most 
probably reflect the heterogeneous group that MCI comprises and diversity in diagnostic criteria 
used. Furthermore, there are seldom measures specifically designed to assess QoL within MCI, 
which is important given the differences between MCI and dementia functions. There is a need 
for further longitudinal evidence to understand the impact a diagnosis of MCI has on QoL and 
thus design interventions to best support the MCI population and maximise their QoL where 
needed.  
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ABSTRACT 
 
Background: The Four Mountains Test (4MT) has been shown to capture impairment in 
hippocampus-dependent allocentric memory in early Alzheimer’s Disease (AD) thus 
demonstrating potential as a helpful diagnostic aid.  
Aims: The study aimed to explore the clinical utility of the 4MT as an early diagnostic aid by 
understanding how 4MT performance relates to dementia type in a memory service.  
Design: A cross-sectional study was conducted within a memory service. Neuropsychological 
tests alongside the 4MT were administered in a face-to-face research appointment. A total of 35 
participants with a range of mild dementias were recruited including AD, vascular dementia, 
mixed dementia, and MCI.  
Measures: Measures of allocentric memory processing (Four Mountain Test; 4MT), estimated 
premorbid functioning (Test of Premorbid Functioning; TOPF), executive functioning (Trail 
Making Test; TMT) cognitive functioning (Addenbrooke’s Cognitive Examination-III; ACE-
III), depression and anxiety (Hospital Anxiety and Depression Scale; HADs) were administered.  
Results: No statistically significant results were found in 4MT performance for AD participants 
versus other dementia types, and no specific factors influencing or predicting dementia 
diagnosis type. Visuospatial abilities and executive functions significantly correlated with 4MT 
scores in the other dementia type groups but no correlations were found in the AD group. All 
dementia groups differed significantly from healthy control data taken from a previous study 
(Bird et al, 2010).  
Conclusions: The utility of the 4MT maybe compromised within a clinical setting and most 
particularly with the influence of participants with vascular dementia. The findings are 
discussed with reference to limitations, clinical implications and recommendations for future 
research.  
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INTRODUCTION 
 
Dementia 
The prevalence of dementia worldwide is estimated at 35.6 million with this set to double by 
2030 and triple by 2050 (World Alzheimer Report, 2012). It has an enormous impact on health 
and social care services (Department of Health, 2009) and improving care for dementia has 
become a national priority (Department of Health, 2012). Dementia is an umbrella term used to 
describe a set of symptoms such as loss of memory, mood changes, and communication 
difficulties caused by certain neurodegenerative conditions usually associated with ageing. 
There are many different dementia types and some are more common than others.  
 
Alzheimer’s Disease 
Alzheimer’s Disease (AD) is a neurodegenerative disorder and the most common cause of 
dementia. It initially affects mediotemporal structures, particularly the hippocampus, but over 
time more brain regions are damaged and symptoms worsen. The most common early symptom 
is episodic memory impairment but as the disease progresses other cognitive domains are 
affected (e.g. executive functioning, language, visuospatial functioning). A certain diagnosis of 
AD is reliant on an autopsy therefore all AD diagnoses are considered probable until confirmed 
otherwise (Agamanolis, 2014).   
 
Vascular Dementia 
Vascular Dementia (VD) is the second most common type of dementia, occurring because of 
diseased blood vessels reducing blood supply to the brain. This usually begins suddenly after a 
cerebrovascular disease (e.g. stroke). VD commonly progresses in a ‘stepped way’ where 
symptoms remain constant for a time and then may rapidly deteriorate (Jagust, 2001; Micieli, 
2006; Román et al, 1993; Sachdev et, 1999). Difficulties in executive functioning, speed of 
processing, reduced concentration and sudden confusion are often the earliest symptoms. 
However, there is overlap in symptoms with AD dependent on the location of the brain injury 
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i.e. memory, visuospatial and language difficulties. The risk factors are those that contribute to 
cardiovascular diseases some of which can be controlled via lifestyle and others that can not due 
to age and genes.   
 
Mixed dementia  
At least 10 per cent of people with dementia are diagnosed with a mixed dementia meaning the 
abnormal protein deposits associated with AD coexist with blood vessel problems linked to 
VD. The symptoms may vary dependent on the brain region affected and similar to those of 
either AD or VD. Research from autopsies suggests the condition is significantly more common 
than realised but the prevalence of this diagnosis is still not known (Bowler, 2002).   
 
Other Dementias 
Fronto-temporal lobe Dementia (FTLD) is associated with frontal lobe cell damage, being 
characterised by changes in personality and behavior, and difficulty with language. Other forms 
of dementia include Lewy bodies (DLB) and Huntington's disease, which rarely present to 
memory services. 
 
Mild Cognitive Impairment 
Mild cognitive impairment (MCI) is classified as the intermediate state between healthy 
cognition and dementia. It is defined by the presence of a memory or cognitive complaint in the 
absence of dementia and minimal or no deficits in daily living (Winbald et al, 2004; Petersen, 
2003; 2004). Some research suggests MCI increases the risk of developing AD with conversion 
estimates varying from about 7-16% per annum (Ganguli et al, 2004; Petersen et al, 2005). 
However, many people with MCI remain stable or eventually improve. There are two main MCI 
subtypes; amnestic MCI (aMCI) that is associated with memory impairments and non-amnestic 
MCI (naMCI) that is associated with other cognitive impairment. Research has also shown that 
people with aMCI have a greater progression to dementia that those with naMCI, however, most 
MCI cases remain stable (Ganguli et al, 2011).  
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Early Diagnosis of AD 
Being the most common dementia, AD has become a particular public health concern with a 
need to improve diagnosis and management. There have been a number of significant 
developments made in pharmacological and psychosocial interventions that are most effective 
when initiated early in the disease (Mittelman et al, 1996; Gaugler et al, 2005; Molinuevo et al, 
2009; Rountree et al, 2009). The neurodegenerative processes of AD often precede clinical 
onset making it difficult to detect AD in the earliest stages when memory deficits are less overt 
and symptoms are often more vague (e.g. disturbance of daily functioning) (Morris, 2005). This 
makes it difficult to differentiate between early AD and normal aging or other forms of 
dementia thus having implications for prognosis and management. Furthermore, differentiating 
AD from other dementia types is particularly difficult due to considerable overlap in both 
pathology and behavioral symptoms (Boyle, 2001; Rosenstein, 1998). There is a growing need 
for clinical instruments that target early deficits of AD so accurate differentiation between other 
forms of dementia and healthy ageing can be made (Prince et al, 2011).  
 
AD and Topographical Disorientation 
One of the earliest clinical manifestations of AD is topographical disorientation (TD) that 
reflects a deficit in spatial memory i.e. the ability to encode, store and retrieve spatial 
information. Successful topographical orientation has been proposed to depend on the 
continuous construction of abstract representation known as a “cognitive map” (Gallistel, 1990; 
O’Keefe & Nadel, 1978; Tolman, 1948). Many studies have investigated TD in AD with a view 
to identify early cognitive markers (Gazova et al., 2012; Iachini et al., 2009; Lithfous et al., 
2013; Vlcek & Laczó, 2014).  
 
Spatial Memory  
Research with animals and humans distinguish between two types of basic spatial representation 
that form the basic structure of spatial memory and allow for spatial navigation (Klatzky, 1998). 
The first is egocentric representation where locations are represented by an individual’s 
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orientation (self-centered) and are dependent mainly on the parietal cortices and caudate nucleus 
brain regions (O’Keefe & Nadel, 1978; Maguire, 1998; Packard, 2002; White & McDonald, 
2002, Weniger et al, 2009). The second is allocentric representation where locations are 
unrelated to the individual’s orientation (world-centred) and centred on objects and/or 
environmental characteristics. Allocentric encoding provides enduring and flexible mental 
representations that are stored in long-term memory, and thus related to the development of 
cognitive maps (O’Keefe & Nadel, 1978; Tolman, 1948).  
 
Hippocampus and Allocentric Representations  
The hippocampus is believed to play a significant role in allocentric representation and memory 
(Maguire, 1998; Packard, 2002; White & McDonald, 2002, Weniger et al, 2009; O’Keefe & 
Dostrovsky, 1971). Animal studies in the 1970’s first demonstrated a link between the 
mammalian hippocampus and allocentric processing on finding ‘place cells’ in the hippocampus 
of rodents (O’Keefe, 1976). It was found that the firing of these cells encoded the specific 
location of the rodent independent of the heading direction and in relation to environmental 
boundaries (Muller, 1996; O’Keefe & Burgess, 1996; Cressant et al, 1997). More recently, 
human studies have likewise associated hippocampal processing with spatial memory for 
locations irrespective of viewpoint and orientation environment (Abraham et al, 1999; 
Holdstock et al, 2000; King et al, 2002; Ekstrom et al, 2003) and in relation to environmental 
boundaries (Doeller et al, 2008). 
 
AD and Allocentric Representation 
The initial stages of AD are associated with pathology in the hippocampus that has been shown 
to predate the onset of symptoms in patients with AD (Alafuzoff et al, 2008; Braak et al, 2006; 
Braak & Braak, 1991, 1996; Dickson, 1997; Morris et al, 1996; Thal et al, 2002; Schott et al, 
2003). Many studies have provided evidence of impairment in allocentric hippocampal 
dependent memory rather than egocentric parietal representation in patients with early AD 
degeneration (Maguire & Cipolotti, 1998; Chan et al, 2001; Galton et al, 2001; Kalova et al, 
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2005; Burgess, 2006). Research suggests therefore that the hippocampal degeneration 
associated with AD therefore diminishes the ability to construct and maintain a long-term 
allocentric representation of the surrounding environments. Studies have indicated that 
impairment in allocentric representations could be a helpful cognitive marker and tests that 
target this maybe reliable tools in facilitating early AD diagnosis.  
 
Four Mountains Test 
Four Mountains Test (4MT) is a memory test developed by Hartley et al (2007) to investigate 
topographical processing in humans. It was specifically designed to capture hippocampal 
dependent allocentric memory abilities. The test uses computer-generated landscapes containing 
four mountains where the topography of the landscape (i.e. the geometry of the surface) and its 
non- spatial visual features can be independently varied. It assesses a person’s ability to 
recognize places from their layout even when the viewpoint changes (see Method section for 
detail). Hartley et al (2007) found that patients with damage to the hippocampus had particular 
difficulty with the test demonstrating the hippocampal role in allocentric memory processing. 
 
Bird and colleagues (2010) adminstered the 4MT to a mild dementia population to investigate 
the core cognitive processes underpinning TD in AD patients comparing performance with 
presentations of MCI, FTLD, subjective memory impairment (SMI) and age matched controls. 
They found that short-term retention of topographical information was impaired in patients with 
AD and an MCI but not in patients with FTLD or SMI. This further demonstrated an inability to 
form and retain allocentric representations of large-scale environments in AD due to 
hippocampal atrophy. The authors argued that the 4MT could be a helpful tool to aid earlier 
diagnosis of AD. However, no study to date has included patients with VD and thus their 
performance on the 4MT is unknown.  
 
Current Study  
Research demonstrates that a core deficit in early AD is the ability to form and retain allocentric 
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representations of large-scale environments due to hippocampal atrophy (Laczó et al, 2009; Bird 
et al, 2010; Vlcek, 2011; Gazova et al, 2012). Thus, adding allocentric memory tests to 
neuropsychological batteries could facilitate differentiation of AD from other types of dementia 
and healthy aging thus facilitating early diagnosis. The 4MT has been demonstrated to 
specifically target the hippocampus and the allocentric topographical processing associated with 
this area of the brain (Hartley et al, 2007; Bird et al, 2010). Furthermore, patients with AD and 
aMCI had impaired performance on the 4MT compared to other memory disorders. However, 
this was conducted in an experimental setting and excluded other major forms of dementia (e.g. 
vascular dementia). Therefore little is known about the relationship the 4MT has with other 
dementia types and within a clinical setting, where presentations may overlap in symptoms and 
differentiation is complex. The test’s relationship with dementia type within a clinical setting 
needs to be established to better understand it’s potential utility as a screening tool to 
differentiate early AD from other forms of dementia and healthy aging thus supporting 
diagnosis and treatment.  
 
To accurately understand 4MT clinical utility certain cognitive abilities need to be controlled for 
using neuropsychological tests! ,-!provide an indication of whether any may have confounded 
4MT performance.!Visual-spatial and scanning abilities are essential for engagement with 4MT 
due to the visual nature of the test. Comprehending (language) and remembering (memory) task 
instructions alongside expressing answers (fluency) and needing to inhibit, plan and problem 
solve (executive functioning. inhibition) are also important skills necessary for engagement. 
Premorbid functioning ability is known to influence rate of cognitive decline and thus potential 
confound on 4MT performance (Sharp, & Gatz, 2011). Depression and anxiety are also known 
to negatively impact memory thus potentially interfering with 4MT performance (Burt, Zembar 
& Niederehe, 1995). The neuropsychological tests used to measure these abilities are described 
in the Methods section.  
 
Aim 
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The aim of this study was to investigate the application of the 4MT in a clinical setting to 
understand how performance relates to dementia type at the earlier stages of the disease. This is 
the next step in understanding the potential utility of the 4MT as a tool to differentiate between 
AD, in the early stages and normal ageing as well as forms of dementia. Given the 4MT has 
only so far been applied in small-scale experimental research it is also important to consider the 
feasibility of using this test within a clinical context with people with mild dementia. Therefore, 
the current study will consider the initial feasibility of using the 4MT in a memory service as a 
way to further understand the clinical utility.  
 
Hypotheses 
1. Participants with AD will have significantly lower 4MT scores than participants diagnosed 
with other forms of dementia including VD and mixed dementia or MCI.  
2. Participants with AD will have a greater reduction 4MT scores compared with normative 
data from healthy volunteers than participants with other forms of dementia.  
3. There will be a positive correlation between 4MT scores and memory scores compared with 
other cognitive functions for participants with different dementias. 
4. An exploratory hypothesis was included to understand whether 4MT scores or any of the 
measured variables were predictors of a diagnosis of AD or other forms of dementia. 
5. The 4MT will be feasible to use within a clinical setting with patients with mild dementia. 
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METHOD 
 
Design 
A cross-sectional observational design was used to explore how performance on the 4MT is 
related to type of dementia diagnosis and performance in other cognitive domains. All 
participants completed the neuropsychological battery of tests and 4MT.  
 
Setting  
The study took place across two NHS Memory Services and their associated Dementia Advisor 
services provided by the Age Concern Charity. These services were located in West London. 
The majority of the research appointments were conducted at the participant’s home (32), 
however, a smaller number were conducted at the memory service (3). The study was conducted 
as part of wider dementia study exploring the accessibility of Cognitive Behavioural Therapy 
(CBT) for people with dementia. The wider study aims to understand the ability of people with 
dementia to perform the core cognitive abilities required to benefit from CBT treatment. 
Participants in this study therefore completed measures assessing cognitive mediation, 
thought/feeling/behaviour differentiation, emotion recognition and association of emotion with 
event alongside the subset of measures used in this study (see appendix 2). 
 
Participants  
Inclusion/exclusion criteria 
All participants who had been referred to memory services or were involved with the dementia 
advisor services were initially considered eligible for the study. Participants invited to 
participate had met the following inclusion criteria:  
 
- Fluent in English language and did not require use of an interpreter 
- Aged 50 years or over 
- Scored above 70 on the Addenbrooke's Cognitive Examination- III at the initial assessment 
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(ACE-III) 
- No current significant mood or anxiety disorders, psychotic symptoms, substance misuse 
problems or a premorbid learning disability 
- No sensory difficulties that would interfere with completion of neuropsychological 
measures i.e. problems with sight 
- Deemed to have capacity to consent to take part in the study 
 
Thus the sample included patients with a range of memory difficulties and subsequent dementia 
diagnoses. Scores below 70 on ACE-III tend to be indicative a more moderate to severe 
dementia and more global deficits on functioning can be expected regardless of dementia type. 
The study aimed to explore early diagnosis and differential cognitive profiles are unlikely to fall 
into this category thus these participants would be unlikely to fall into this category. 
Furthermore, floor effects on 4MT would be expected. Participants with ACE-III scores above 
70 were also considered likely to have retained capacity to consent to research. Further to this, 
the researcher re-assessed capacity to consent in accordance with the Mental Capacity Act 
(2005) at the research appointment.  
 
Diagnostic assessment 
Diagnosis of dementia was given in accordance with ICD 10 criteria following a clinical 
interview and assessment of cognitive ability using ACE-III. A clinician from the memory 
service conducted the diagnostic assessment. In most cases this was substantiated via an MRI 
and in certain cases when a presentation was more complex then participants were referred for 
further neuropsychological testing. Results from all assessments were discussed in a multi-
disciplinary team and a diagnosis was decided. Following this, patients were assigned an 
allocated clinician who disclosed the diagnosis.  
 
Ethics 
Ethical approval for this study was granted after review by the City Road and Hampstead 
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National Research Ethics Service Committee (see Appendix 3 for ethical approval letter). The 
study was also registered with local research and development departments associated with the 
memory services.  
 
Sample Size  
A power analysis was conducted to estimate the required sample size for this study and reduce 
the possibility of the findings being underpowered. The power analysis was predicated on using 
logistic regression analysis to explore the main aim of the study, which was to understand the 
whether 4MT performance can predict dementia diagnosis type. Furthermore, logistic 
regression is a less powerful form of analysis and therefore establishing the sample size using 
this statistic would result in a larger sample size that would ensure that all other statistical 
analysis used in this study were adequately powered (i.e. Independent Samples and One Sample 
t-tests, Pearson’s Correlation Coefficients).” The effect size for the difference on these 
performances was identified as medium (d= 0.58) based on research using the 4MT in a similar 
sample (Bird et al, 2010). Chinn’s (2000) equation was to used to provide an approximate odds 
ratio (the d value is multiplied by 1.81 and then this result is anti-logged).  Using the d = 0.58, 
an odd’s ratio of 2.86 was calculated using this equation. The sample size was calculated (using 
GPower3) with this odds ratio of 2.86, and with alpha setting at 0.05 and power at 0.80. This 
produced a sample size estimate of 44 (N=44) with a power of 0.81 for this study.  
 
Measures  
Neuropsychological measures were administered to characterise the sample and examine 
relationships between 4MT and other abilities. The researcher was trained and experienced in 
administering neuropsychological tests. Demographic information was also collected both 
during the testing and retrospectively using the NHS electronic patient database. The orders of 
the tests in the battery were randomized using Qualtrics, an online survey system designed for 
administering research protocols. This enabled the researchers to control for the potential impact 
of fatigue and carry-on effects on performance.  
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Test of Premorbid Functioning (TOPF) (Welscher, 2011) was administered to estimate 
premorbid cognitive functioning prior to the onset of the dementia. The TOPF is based on a 
reading paradigm that requires pronunciation of 70 atypical words (e.g. paradigm) that have 
irregular grapheme-to-phoneme translation. This test was administered using a face-to-face 
interface and in accordance to the standardized instructions. Overall TOPF reliability is high, 
with good internal consistency (Chronbach’s alpha = 0.95). Test-retest reliability of the TOPF is 
also good (corrected correlations between r=.89 and r=.95; Wechsler, 2011). The TOPF also 
correlates to Wechsler Adult Intelligence Scale- Fourth Edition (WAIS-IV) Full Scale IQ scores 
(R=.72, p<0.001; R2=0.52, P<0.001). Premorbid IQ can be calculated from the raw score, 
adjusted for sex and years of education or other demographic variables. It can be used to predict 
therefore sub-scale scores on the WAIS-IV and Wechsler Memory Scale (WMS). Research 
demonstrates the TOPF as a valid method for assessing change between premorbid and current 
cognitive functioning with a clinical dementia sample (Duff, Chelune and Dennett, 2011).  
 
The Addenbrooke's Cognitive Examination-III (ACE-III; Mioshi et al, 2006) is the updated 
version of the ACE-R (Mioshi et al, 2006) designed to assess five cognitive domains 
attention/orientation, memory, verbal fluency, language and visuo-spatial abilities. The test was 
administered following the instructions detailed in the manual. Each cognitive domain involves 
the completion of a series of pen to paper tasks (see Appendix 4). The total score is 100; higher 
scores reflect better ability. The ACE-III is minimally adapted from ACE-R, which has been 
extensively validated within a dementia population (Hsieh et al, 2013). Cognitive domains in 
the ACE-III correlated significantly with corresponding standardized neuropsychological tests 
(Hsieh et al, 2013). It also compared favourably with the ACE-R (r= 0.99, p < 0.01), with 
similar levels of sensitivity and specificity (Hsieh et al, 2013). The ACE-III was designed to be 
sensitive to early stages of dementia and demonstrates high sensitivity and specificity at cut-offs 
previously recommended: with cut offs of 88 (sensitivity = 1.0; specificity = 0.96) and 82 
(sensitivity = 0.93; specificity = 1.0). Internal reliability of the ACE-III, measured by 
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Cronbach's ! coefficient, was 0.88.  
 
Trail Making Test (TMT) (Reitan, 1958; 1992) is a visual attention and task-switching test. It 
consists of two parts involving connecting a set of twenty-five consecutive symbols (A: 
numbers and B: numbers and letters) as fast as possible while maintaining accuracy. It measures 
complex visual scanning (Shum, McFarland & Bain, 1990), speed of processing (Lezak, 1995), 
cognitive flexibility and executive functioning (Gaudino, Geisles & Squires, 1995). This test 
was administered face to face and in accordance to the standardized instructions. Test-retest 
reliability is reported at r=0.80 (Spreen & Strauss, 1991) and validity r= 0.59 (Delis, Kaplan & 
Kramer, 2001). It has been used extensively in work with dementia (Strauss, Spreen & 
Sherman, 2006) and is sensitive to the detection of cognitive impairment including 
AD (Tombaugh, 2004). Longitudinal studies have found that as subjects become older, the time 
required to finish the TMT, in particular part B, increases significantly and that this time is 
significantly longer in older patients with dementia (Rasmusson, et al, 1998). Higher test times 
suggest poorer performance, whilst lower times reflect better. The raw score of times in seconds 
and number of errors made were converted used for analysis using the Ashendorf and 
colleagues norms adjusted for age and years of education (Ashendorf et al, 2008).  
 
The Hospital Anxiety and Depression Scale (HADS) is a 14 item questionnaire that produces 
two 7-item subscales assessing depression and anxiety over the preceding two weeks. It is a 
self-assessment rated on a four-point likert scale, with a maximum score of 21 on each subscale 
(higher scores correspond to higher symptom severity; Johnston et al, 2000; Herrero et al, 
2003). Importantly, it deliberately leaves out physical indicators of psychological distress such 
as dizziness, headaches, insomnia, and fatigue, to prevent interference with somatic disorders 
making it suited for the detection of depression in older adults (Herrmann, 1997; Bjelland et al, 
2002; Wang et al, 2006). Symptoms of severe psychopathology are also omitted to avoid the 
“floor effect” frequently encountered in non-psychiatric patients (Herrmann, 1997; Bjelland et 
al, 2002). The scale has a high internal consistency with a Cronbach’s ! coefficient of 0.7–0.9 
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(Herrmann, 1997; Aben et al, 2002; Bjelland et al, 2002; Herrero et al, 2003; Lowe et al, 2004; 
Bambauer et al, 2005; Thomas et al, 2005). Two-week test–retest reliability is also high (r > 
0.80), demonstrating a satisfactory stability of the scale (Herrmann, 1997). It has been used 
successfully in research settings with dementia (Samaras, 2013). In this study, the HADS was 
administered as a semi-structured interview rather than an independent questionnaire in 
accordance with other dementia studies (Samaras et al, 2013). 
 
The 4MT is a memory test designed to measure hippocampal dependent topographical memory 
processing in humans. The 4MT is an experimental test that has only previously been used in a 
series of laboratory based research studies and thus the psychometric properties are yet to be 
formally established. However, in terms of the validity of the measure research has 
demonstrated that the 4MT is sensitive to hippocampal volume, which specifically influences 
performance on the allocentric memory subtest (Hartley and colleagues, 2007; Bird et al, 2010; 
Kuven et al, In Press). This provides evidence that the 4MT captures the hippocampal 
dependent allocentric ability it was designed to measure. 
 
The original test developed by Hartley and colleagues (2007) was comprised of 4 subtests 
independently assessing perception and short-term retention of differing information contained 
in computerised landscape pictures administered in an A4 booklet (see Hartley et al, 2007 for 
details). Hartley and colleagues later redesigned the test into a computerised version that solely 
administered the topographical memory subtest of the 4MT. The test therefore comprised of a 
series of 30 computer-generated landscapes of 4 mountains in the central foreground (see figure 
1). Stimuli were constructed by varying the topographical (i.e., surface geometry) and non-
spatial (e.g., lighting, cloud cover) features of the landscape and the viewpoint from which 
landscapes were observed. Participants were presented with a “sample” image on a computer 
screen for 10 seconds and then a blank screen for approximately 2 seconds. On the next 
computer slide 4 alternative landscape scenes were presented that were arranged randomly in a 
2 by 2 grid. To prevent participants being misled by local matches with small-scale features 
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each of the four stimuli were rendered from a different camera position.  Furthermore, the 3 
alternative responses were also rendered from different prevailing conditions from the sample 
image as well as each other. Participants had 20 seconds to select the correct test image. The 
task was to identify the target image were all topographical information is preserved but the 
viewpoint has been changed. Answers were recorded independently by the participant using the 
provided grid sheet (see Appendix 4). The test was administered on a laptop but the researcher 
controlled the laptop and the timings of the images at all times to reduce need for participants to 
interact with the computer interface and minimize potential confounds. 
 
Procedure 
All patients referred to the memory clinic for an assessment during the recruitment phase of the 
study were considered to take part. Patients who had previously joined a trust wide NHS 
research register, who granted consent to be contacted about research being conducted, were 
contacted following dementia diagnosis disclosure. In addition clinician’s follow up caseloads 
were frequently reviewed to identify potential participants who may have not signed the 
research register. These potential participants were contacted prior by the involved clinician to 
gain permission to be contacted about research. Identified participants were then screened 
against the inclusion criteria outlined above by the researcher. This information was obtained by 
accessing patient’s files on an electronic patient database. Participants were then contacted by 
the researcher via telephone to outline the main aims and procedures of the project. A research 
appointment was also arranged, which took place in either the participant’s home or the memory 
clinic dependent on their preference. Information sheets were also posted to participants prior to 
the visit (see Appendix 6). The study information sheet was reviewed again jointly at the visit to 
ensure participants understood the study aims and requirements. Written consent was then 
gained from each participant whom had capacity and demographic information collected (see 
Appendix 7). The neuropsychological tests were administered (see measure section). An 
electronic data system was used for in vivo entry of the raw data. The research sessions lasted 
approximately 2 hours and all participants were debriefed at the end of the testing. The 
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researcher remained blind to the type of dementia the participant had until data was collected 
when dementia diagnosis was matched to the data. This study formed part of a wider project and 
therefore further questionnaires were also administered during these appointment but were not 
relevant to the aims of this study.  
 
Data Analysis  
Data was entered and analysed using the Statistical Package for the Social Sciences version 
17.0. Initial descriptive exploration of the data was conducted to investigate distribution and 
representativeness. Independent Samples T-Tests were conducted to investigate differences in 
4MT scores for AD versus other forms of dementia. One Sample T-Tests were also computed 
using control data from Bird et al (2010) study to compare how dementia 4MT scores differed 
to cognitively healthy controls. A series of Pearson’s Correlation Coefficients were also 
conducted to explore relationships between scores on the 4MT, scores on the background 
neuropsychological tests and different dementia diagnosis. A logistic regression was finally 
conducted to explore further if any measured variables predicted dementia diagnosis.  
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RESULTS 
 
Eighty-Eight participants were initially identified as prospective participants (66 memory 
service; 22 Age Concern). Twenty-six potential participants were excluded at the initial 
screening phase for not meeting the inclusion criteria i.e. ACE below 70 (14), current mental 
health difficulties (4), no diagnosis of dementia (6), physical health difficulties (1) and required 
an interpreter (1). Thirty-six participants who met the inclusion criteria did not take part in the 
study for reasons including not wanting to take part (23), unable to make contact (9), had been 
admitted to hospital or care home (3), or had significant visual impairment (1). Subsequently, 
consent was obtained from 35 participants (19 memory service; 16 Age Concern). Meanwhile, 3 
participants terminated the 4MT during administration reporting that they found it too 
challenging and these cases were excluded from the main analysis of the 4MT being deemed to 
represent floor effects. Data was therefore analysed for 32 participants in relation to the 
hypothesis, meaning the study was slightly underpowered; the results below should therefore be 
treated with caution. Prior to the research appointment all participants had a scored above 70 on 
the ACE-III at initial memory service assessment, in line with the inclusion criteria. However, 
when the ACE-III was re-administered to participants at the research appointment it was 
discovered that five participants scored below 70 on the ACE-III. An exploratory analysis was 
performed with these participants included and then excluded from the data. The exclusion of 
these participants did not change the results and so a decision was made to include these cases 
in the analysis.   
 
Participant Characteristics 
The demographic information and baseline neuropsychological scores for the sample (N= 32) 
are presented in Table 1. There were no significant differences between any of the dementia 
groups in terms of age, gender and years of education when compared separately (see Table 2).  
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Table 1: Demographic and clinical characteristics of participants (N=32) 
           N % Mean SD Range 
Age (years) - - 78.57 6.76 58-91 
Years of Education - - 13.88 3.93 7-25 
ACE score - - 74.77 13.44 38-96 
Dementia Diagnosis       
AD 14 43.8 - - - 
Vascular Dementia 8 25.0 - - - 
Mixed Vascular and AD 5 12.5 - - - 
MCI 4 15.6 - - - 
Other 1 3.1 - - - 
Gender      
Female 15 53.1 - - - 
Male 17 46.9 - - - 
Ethnicity       
White British 17 53.1 - - - 
Irish 1 3.1 - - - 
White Other  8 25.0 - - - 
Black Caribbean 2 6.3 - - - 
Indian 2 6.3 - - - 
Bangladeshi 2 6.3 - - - 
Baseline scores       
Anxiety - - 6.84 3.57 0-14 
Depression  - - 6.06 3.62 1-13 
Estimated Premorbid functioning - - 48.44 16.86 10-70 
Memory  - - 15.93 4.99 15.93 
4MT - - 10.88 3.42 3-18 
Visuospatial - - 13 2.05 10-16 
Mean scores with standard deviations and the range. Neuropsychological data based on raw 
scores for ACE, TOPF and HADS.  
 
Neuropsychological Assessment 
Independent sample t-tests indicated no significant differences in the cognitive or psychological 
domains between AD and other dementia types groups for the sample (N= 32). There were no 
significant differences also on cognitive and psychological measures between AD and VD 
groups (N=22). Furthermore, on checking the distribution of scores on measures the zero scores 
were not outliers, but rather were consistent with the variance of the sample - hence they were 
maintained in the analysis even though technically these scores were slightly below chance 
performance. The full breakdowns of test scores are detailed below in Table 2.  Pearson’s 
Correlation Coefficients were also employed to investigate relationships between measured variables 
when split by AD or other dementia type and VD (see appendix 7).  
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Table 2: Mean and standard deviation scores of test scores for each type of dementia (N=32) 
 
Mean scores with standard deviations and the range. Neuropsychological data based on raw 
scores for ACE, Trails Making Test, TOPF, HADS. 
aOther dementia category not included in breakdown as only 1 participant but is included in the 
wider other dementia type sample 
Dementia Diagnosis  
AD 
(N=14) 
VD 
(N=8) 
MCI 
(N=4)   
Mixed AD & VD 
(N=5) 
Other Dementia Typea 
(N=18)  
Age  
(Years) 
77.42 
(6.24) 
63-87 
78 
(8.73) 
58-86 
77.25 
(6.29) 
70-83 
82.8 
(5.93) 
77-91 
79.37 
(7.03) 
58-91 
Education  
(Years) 
14.79 
(4.23) 
10-25 
14 
(4.44) 
7-19 
12.75 
(3.5) 
9-17 
12.8 
(2.95) 
10-17 
13 
(3.62) 
7-19 
4MT 10.43 
(3.82) 
3-18 
11 
(3.74) 
7-17 
13 
(1.83) 
11-15 
10.8 
(3.03) 
7-15 
11.16 
(3.08) 
7-17 
ACE-III Total  75.69 
(10.22) 
64-96 
75.63 
(13.03) 
54-90 
83.33 
(9.07) 
75-93 
73.20 
(16.04) 
45-85 
74.61 
(15.45) 
38-93 
ACE-III Memory  14.77 
(4.87) 
8-26 
17.63 
(5.45) 
10-25 
17.67 
(7.37) 
12-26 
16.20 
(3.42) 
11-20 
16.94 
(4.91) 
10-26 
ACE-III Attention 16 
(2.31) 
11-18 
16.38 
(1.59) 
14-18 
15.67 
(.58) 
15-16 
15.40 
(2.07) 
12-17 
15.72 
(2.14) 
10-18 
ACE-III Language  22.23 
(3.0) 
17-26 
21.75 
(3.01) 
17-24 
25 
(1.0) 
24-26 
19.80 
(7.46) 
7-26 
21.39 
(5.10) 
7-26 
ACE-III Visuo-spatial 13.46 
(1.66) 
10-16 
12.25 
(2.12) 
10-16 
14 
(3.46) 
10-16 
13 
(1.87) 
11-15 
12.61 
(2.23) 
10-16 
ACE-III Fluency  9.23 
(2.13)  
6-13 
7.63 
(3.25) 
1-11 
11 
(1.0) 
10-12 
8.80 
(3.70) 
4-13 
8.33 
(3.43) 
1-13 
Trails Making A  
(Seconds) 
54.01 
(25.1) 
26-98 
69.88 
(42.19) 
33-160 
39 
(10.55) 
26-49 
48.40 
(15.24) 
30-63 
55.79 
(30.74) 
26-160 
Trails Making B 
(Seconds) 
129.75 
(81.89) 
64-279 
187.33 
(76.79) 
105-257 
105 
(24.88) 
49-78 
73.50 
(40.3) 
45-102 
128 
(68.39) 
45-257 
TOPF 50.7 
(14.22) 
24-70 
48 
(19.12) 
23-69 
54.75 
(11.59) 
38-63 
46.20 
(21.67) 
10-65 
46.58 
(18.61) 
10-69 
Anxiety 6.64 
(2.90) 
2-13 
8.25 
(3.77) 
3-14 
6 
(6.24) 
1-13 
4.80 
(3.11) 
0-8 
7 
(4.0) 
0-14 
Depression 5.93 
(3.73) 
2-13 
7 
(3.5) 
2-11 
3.33 
(.58) 
3-4 
6.20 
(4.82) 
1-13 
6.17 
(3.54) 
1-13 
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Current sample vs. Bird study sample 
Demographic and neuropsychological characteristics of the participants in the current study and 
Bird et al (2010) are shown in Table 3. The Bird control group consisted of spouses/partners of 
the participating patients and other age-matched adults recruited through a volunteer database. 
The Bird control participants had younger mean ages than the AD and other the dementia type 
participants in the current study. The AD participants in the current study and the Bird control 
participants were comprised of a similar ratio of male and females, with more males compared 
to females. The other dementia group had more equal numbers of males and females. In terms 
of premorbid functioning, the Bird control had a higher mean predicted IQ scores (within the 
high average range) than the AD and other dementia type participants in the current study 
(within the average range). 
 
Dementia groups in the both studies were comprised of participants in the earlier stages of the 
disease. Reliable comparisons of disease severity of the Bird AD group to the AD and other 
dementia type group in the current study were not possible as different neuropsychological 
measures were used to measure overall cognitive functioning. All of the Bird AD participants 
were experiencing mild dementia (MMSE = 26.1, SD = 2.8) and had been provided with a 
formal diagnosis of probable AD. The majority of AD (ACE-III = 75.69, SD = 10.22) and other 
dementia participants (ACE-III = 74.61, SD= 15.45) in the current study were also experiencing 
mild dementia and all had been provided with a formal diagnosis of dementia. The Bird AD 
participants had higher mean predicted IQ scores (within the high average range) than the AD 
and other dementia type participants in the current study (within the average range). There were 
no significant differences in the AD participant’s 4MT scores in the current study (M=10.46, 
SD=3.971) and those in the Bird study AD (M=12.2, SD= 5.34) (t(13)= -1.736, p= .106). Bird 
et al (2010) did not include a VD group so comparison cannot be made in this analysis. Please 
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see Figure 1 for comparisons of 4MT scores between all groups in the current study and the 
Bird control and AD groups. 
 
TABLE 3: Demographic and neuropsychological data from the current study and Bird study  
Group N Sex 
(F:M) 
Age Estimated Premorbid 
 Functioning 
4MT scores 
AD  
(Bird Study) 
7 2:5 65.3 
(11.0) 
57–79 
114.3 
(8.7) 
90–128a 
12.2 
(5.34) 
4-20 
AD 
(Current Study) 
14 5:8 77.15 
(6.4) 
63-87 
105.2 
(11.8) 
 
10.46  
(3.97) 
3-18 
Controls 
(Bird Study) 
25 9:16 65.3 
(7.6) 
51–79 
112.7 
(12.2) 
85–130a 
21.4 
(3.34) 
16-30 
Other dementia  
(Current Study) 
18 10:9 79.37 
(7.03) 
58-91 
101.7 
(15.1) 
 
11.16 
(3.08) 
7-17 
Mean and Standard deviations. Estimated premorbid functioning scores are shown as predicted 
full-scale IQ scores (standardized (z) scores) based on published normative data; n.t., not tested 
aBased on National Adult Reading Test (2nd Ed; Nelson, 1991)  
bBased on TOPF 
 
 
Figure 1: 4MT performance for dementia groups in the current study and Bird study  
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Hypothesis 1: AD participants will have significantly lower 4MT scores than those with 
other forms of dementia  
Independent sample t-tests were conducted to compare 4MT scores for participants with AD 
and other dementia types. There was no significant difference in 4MT scores of AD participants 
(M= 10.43, SD= 3.82) and all other types of dementia (M= 11.16, SD= 3.08) (t(30)= -.559, p= 
.532; d = -.1992; 95% CId= -.5027 - +.8669).Furthermore, no significant differences were also 
found in 4MT scores of AD participants (M= 10.43, SD= 3.82) and VD participants (M= 11, 
SD= 3.74) (t(20)= -.340, p= .665; d = -.1507; 95% CId= -.7211 – +1.0188). A comparison of 
4MT scores of AD participants (M= 10.43, SD= 3.82) and other dementia types excluding those 
with mixed diagnosis (M= 11.29, SD= 3.20) was also conducted but no significant difference 
was found (t(25)= -.556, p= .685; d = -.2142; 95% CId= -.5454 - +.9692).   
 
Hypothesis 2: AD participants will have a greater reduction in 4MT scores compared with 
normative data from healthy controls than participants with other forms of dementia 
Although control data were not collected in this study, tentative comparisons were made using 
one sample t-tests between dementia groups and cognitively healthy participants’ data from the 
Bird et al (2010) study. However, these should be interpreted with caution in light of the 
differences in the characteristics between the Bird control group and the two main dementia 
groups of the current study (i.e. AD and other dementia type group). Overall, the 4MT score for 
the dementia sample collected in this study (M= 10.88, SD= 3.42) differed significantly from 
the control data from the Bird Study (M=21.4, SD= 3.34) (t (31)= -17.387, p < .001). There 
were significant differences were found between control data (M=21.4, SD= 3.34) and the AD 
group (M=10.46, SD=3.971) (t (12) = -9.932, p < .001). Furthermore, significant differences 
were also found in 4MT scores between control data (M=21.4, SD=3.34) and the other dementia 
group (M=11.16, SD= 3.078) (t (18) = -14.505; p= .000).  
NOT identical sample but work limitations of minimal resource.  
 
 
Hypothesis 3: Positive correlation between 4MT scores and memory scores compared with 
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other cognitive functions for participants with different dementias 
Pearson’s Correlation Coefficient were conducted to explore the relationships between 4MT 
scores and other cognitive functions for AD versus other types of dementia. The cognitive 
functions included memory, visuospatial, language, fluency, attention, executive functioning 
and estimated premorbid functioning. There were no significant correlations found between 
4MT scores and memory scores (ACE-III) for either AD (r(10)= -.035, p= .915) or other 
dementia type groups (r( 16)= .016, p= .951). Furthermore, in the AD group there were no 
correlations found between 4MT scores and any other cognitive functions (see table 3). 
However, in the other dementia type group, 4MT scores had a moderate positive correlation 
with TMT B scores (r(16)= .541, p= .017) and negative correlation with visuospatial scores 
(r(16)= -.477, p= .045). However, it should be noted that these findings would not survive 
correction for Type I error across this set of correlations. Neither depression nor anxiety 
correlated with 4MT scores across the dementia groups. 
 
Table 4: Pearson’s Correlations between measured variables and 4MT scores split by 
dementia (N= 32) 
 AD  
4MT 
     Other dementia  
4MT  
 r p value r p value 
ACE total -.195 .544 .312 .208 
Memory  -.035 .915 .016 .951 
Attention .344 .274 .285 .251 
Language -.299 .344 .353 .151 
Visuospatial -.516 .086 .477* .045 
Fluency  .022 .946 .249 .319 
EPF .101 .743 .319 .183 
TMT A -.238 .456 .325 .174 
TMT B .286 .368   .541* .017 
Depression  .008 .980 -.397 .103 
Anxiety .009 .976 -.088 .728 
! &%!
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Hypothesis 4: whether 4MT scores or any of the measured variables were predictors of 
diagnosis of AD or other forms of dementia.  
An exploratory logistic regression was conducted to investigate whether any of the measured 
variables contributed to a diagnosis of AD versus other forms of dementia. Measured variables 
inputted into the regression model were selected based on correlational and clinical significance, 
and included TMT B scores, visuospatial, memory, fluency, 4MT scores, estimated premorbid 
functioning. In step 1, the selected variables were entered into the regression model as 
predictors of dementia diagnosis (i.e. AD or other dementia). The overall model did not classify 
a significant proportion of the individuals (x2(6)= 6.81, p= .339) and none of the variables were 
significant predictors of the outcome, AD or other dementia diagnosis. A stepwise logistic 
regression was also attempted to incorporate all the measured variables in an exploratory 
investigation, however, it was not possible to fit a model better than the constant term.  
 
Feasibility  
A total of 35 participants were recruited to the current study, however, three participants 
terminated the 4MT task during administration. Two of these participants had a diagnosis of 
early AD whereas one participant had a diagnosis of VD. The participant with VD had an ACE-
III score below 70 and low average premorbid functioning. This may have impacted the ability 
to successfully complete the 4MT. The two participants with AD performed well on all 
background cognitive tests suggesting that difficulties with 4MT engagement might be due to 
topographical memory impairment. None of the three participants had depression or anxiety 
scores within the clinical ranges. Two of the three participants terminated the testing half way 
through the administration. Both participants gave the reason that they were finding the test too 
difficult and stressful. The other participant stopped the 4MT during the practice phase, giving 
the reason that the test they found the test trivial and did not feel the need to continue.  
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Based on the 32 participants who completed the test participant scores on 4MT were normally 
distributed with a mean score of 10.87 (SD= 10.87, range= 3–15). The 4MT scores in this study 
where significantly lower than the Bird control data with a mean score of 21.4 (SD= 3.34, range 
=16-30). Only one participant obtained a 4MT score below chance level (<25%) demonstrating 
that participants with mild dementia can effectively complete the 4MT to provide a useful 
measure of topographical memory. Formal feedback about the experience of completing the 
4MT was not collected in this study but the researcher noted qualitative feedback given by 
participants on completion of the task.!The majority of participants reported finding the test 
difficult and had performed poorly. Although the subjective experience of difficulty did not 
appear to result in actual poor performance on the 4MT. A number of participants also 
complained about the length of the 4MT, which took approximately 30 minutes to complete.   
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DISCUSSION 
 
Summary of results 
The current study aimed to investigate the application of the 4MT in a clinical setting to 
understand how performance varies according to dementia type at the earlier stages of the 
disease. Contrary to the hypothesis, 4MT performance was not found to be significantly 
impaired in AD participants compared to other types of dementia including VD. As 
hypothesised, AD participants had significantly poorer performance on the 4MT than the 
control group from the Bird et al (2010) study. This significantly poorer 4MT performance was 
also indicated in comparison of the other dementia type group to the Bird control group. 
However, the control participants were younger with higher estimated premorbid functioning 
compared to the dementia participants in the current study. These findings therefore should be 
interpreted tentatively (see Limitations for further discussion). Statistical analysis of MCI 
participants could not be conducted due to a small sample size. 
 
Opposing another hypothesis, memory performance in AD participants did not correlate with 
4MT performance nor were there any significant relationships found between these two 
variables for any type of dementia. Furthermore, there were no significant relationships between 
4MT and other cognitive functions for AD participants. However, the 4MT performance of 
participants with other forms of dementia had significant relationships with executive 
functioning and visuospatial abilities. Depression and anxiety did not appear to have an impact 
on 4MT performance in any of the dementia groups. Unsurprisingly, on exploration of potential 
predictors of diagnosis of AD versus other forms of dementia there did not appear to be any 
significant predictors of the outcome. Consistent with non-significant finding, CI is broad and 
indicates study is underpowered.  
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Comparison with previous research 
Previous research has demonstrated impairment in allocentric memory in early AD and 
suggested that tests tapping these hippocampal dependent abilities could aid early diagnosis 
(Maguire and Cipolotti, 1998; Chan et al., 2001; Galton et al., 2001; Kalova et al, 2005). The 
results of this study do not correspond with previous research conducted that impaired 4MT 
scores differentiated AD from other dementias in the context of hippocampal damage (Hartley 
et al, 2007; Bird et al, 2010; Kuven et al, In Press). Bird and colleagues (2010) found that short-
term retention of topographical information was impaired in patients with AD but not in patients 
with FTLD or subjective memory impairment. These results also concurred with a recent study 
that found that 4MT topographical short-term memory subtest was impaired in MCI and AD 
patients compared to cognitively healthy controls in both UK and Italy populations and 
correlated with hippocampal volume (Kuven et al, In Press).  
 
Previous studies support the future application of the 4MT in the diagnosis of early AD and to 
differentiate between other forms of dementia or healthy aging. However, a number of 
alternative studies have, to the contrary, demonstrated that the specific impairment underlying 
TD in early AD is the translation between the parietal egocentric and hippocampal allocentric 
representations (Cooper et al, 2001; Maguire, 2001; Vann et al, 2009). Research has suggested 
that this specific impairment is not measured in equivalent allocentric spatial tasks (Morganti et 
al, 2013). These results may coincide with this alternative explanation and account for the non-
significant results i.e. the 4MT is not sufficiently sensitive to the allo- to ego-centric translation 
impairment. However, further research is needed to clarify this tentative comparison.  
 
There are also differences in the recruitment and diagnostic processes of the clinical groups 
between the Bird et al. study and the current study that may contribute to the unexpected 
findings.  Both studies recruited patients experiencing mild dementia and the lack of significant 
differences in 4MT performance across the two AD samples suggests that participants were at 
similar stages of the disease. However, unlike the current study, the Bird AD sample was 
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recruited from a research centre and more extensive diagnostic assessments were conducted (i.e. 
interview, neuropsychological assessment and imaging). Different diagnostic criteria was also 
used to define the AD group, which offers a more in depth cognitive analysis (i.e. NINCDS-
ADRDA for Bird Study). Furthermore, more stringent exclusion criteria were applied to the 
clinical groups including a history of learning disability, and/or below baseline attention ability. 
Thus, comparatively the Bird AD group may comprises a more homogenous and defined group 
of mild AD participants with less co-morbid difficulties, whereas the current AD sample maybe 
more heterogeneous in presentation and severity. Thus, caution should be taken when making 
comparisons between the two studies and may contributed to the conflicting findings. The 
current study was conducted within an affluent area of London, which may have created bias 
and contribute to the findings. However, there is no description of the social factors of the Bird 
et al sample and therefore comparisons cannot be made in terms of the impact affluence may 
have had 4MT and cognitive test performance. 
 
Interpretation of findings  
In this study, VD formed the second largest dementia group in line with national statistics and it 
is possible that the inclusion of this group may account for the conflicting findings. Previous 
studies using 4MT did not include participants with VD, the second most common form of 
dementia to present to memory services (Bird et al, 2010; Kuven et al, In Press). The pathology 
of VD is often heterogeneous and hippocampal atrophy can often be present (Pol et al, 2011). It 
is plausible that the 4MT is therefore not sensitive enough to differentiate between AD and VD 
given the overlap in atrophy and may account for the findings. The lack of significant 
differences in memory performance between AD and other forms of dementia including VD 
supports this interpretation as it could suggest potential hippocampal atrophy in both groups. 
Furthermore, there were a number of participants with diagnosis of mixed AD and VD 
suggesting they may have atrophy to hippocampal regions that may have further reduced the 
other dementia type group 4MT performance. However, on exclusion of participants with mixed 
VD and AD from the other dementia type group the non-significant differences in 4MT 
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remained across the two groups. Thus, supporting the idea of potential pathology and symptom 
cross-over between the AD and VD groups.  
 
The results may also reflect a wider issue in translating laboratory design tests into clinical 
settings and that the 4MT may have poor ecological validity. Often in clinical practise, dementia 
presentations can be complex and diverse thus making it hard to make a clear and definite 
diagnosis. However, being referred to a memory clinic suggests that the patient or a significant 
other is aware of the cognitive symptoms as they are having an impact on daily functioning. 
Thus, samples recruited from memory clinics may include patients with more moderate 
dementias and less patients within the very earliest of stages of the disease for which the 4MT 
has demonstrated utility. It should be considered when interpreting these findings therefore that 
perhaps the results do not suggest a significant flaw within the 4MT but rather a clinical 
dilemma of stage of dementia and the ability to usefully engage with 4MT.  
 
The non-significant differences in 4MT performances between AD and other dementia types as 
well as the lack of correlations with specific cognitive functions are interesting findings. A 
major contributing factor to this may be that the study is underpowered due to a smaller sample 
size than expected, the implications of which are discussed in detail below (see limitation 
section). However, a number of other findings may provide plausible explanations of the 
unexpected results. The significant relationship between visuospatial and 4MT performance in 
the other dementia group is surprising. It can tentatively be inferred that poor abilities in the 
visual domain were influencing poor 4MT performance thus possibly contributing to the 
similarities in 4MT with AD participants. However, in the regression analysis visuospatial was 
not indicated to be a determinant of dementia group and therefore this interpretation remains 
tentative requiring further exploration. There were no significant differences in 
neuropsychological characteristics between the AD group and other dementia type group or the 
VD group. This suggests that participants were similar in areas of neuropsychological 
functioning reducing any confounding influence on 4MT performance that could have 
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contributed to the lack of significant differences across the groups.  Interestingly, when 
participants scoring zero on 4MT (N=32), which can be deemed well below chance thus 
representing a floor effect, were excluded from the neuropsychological score comparisons these 
non-significant differences remained further supporting this assumption.  
 
Limitations 
There are also a number of methodological limitations in this study that may have contributed to 
the non-significant findings. The most significant is the sample size of this study, which is 
smaller than the estimation for sufficient power suggested in the preliminary power analysis. 
However, it is important to note that the estimated sample size was predicated on a medium 
effect size. Therefore, the lack of a findings with 32 participants speaks against a large effect 
but the study was sufficiently powered for d=1 on a t-test if N=32. It can therefore be assumed 
that the study was underpowered to find a medium to large effect size. This may have increased 
the chance of type II errors occurring thus reducing the validity and reliability of the findings. It 
should be noted that a significant effort was made to reach the desired sample size but was 
hindered by limited resources (e.g. sole researcher), strict time constraints (e.g. DClinPsy 
deadlines) and significant staff changes to the recruitment sites.  
  
The cross sectional design of this study is also a limitation and it is not possible to draw firm 
conclusions from these findings especially regarding causal relationships.  Therefore, it remains 
unclear whether the 4MT is a reliable tool that can aid the diagnosis of early AD and whether 
any other cognitive factors influence this relationship. Future studies in this area are encouraged 
to utilise longitudinal designs. Another issue with cross-sectional design is the influence of 
confounding variables. A number of confounds were measured in this study using self-report 
and neuropsychological tests that may have contributed to performance on 4MT (e.g. age, 
education level, visuo-spatial abilities). Elderly participants are particularly vulnerable to 
fatigue and therefore keeping the testing battery short was a priority and the measures included 
were carefully considered to meet the study aims. More in depth measures of cognitive abilities 
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using the WAIS-IV or WMS may have provided more valid indicators of cognitive abilities and 
memory functioning (i.e. delayed vs immediate memory). Furthermore, additional measures 
could have been included to capture further confounding variables such as hearing and visual 
abilities, which would enabled them to be statistically controlled for in the regression model. 
However this may have markedly increased the time required to complete the testing battery, 
which would not have been deemed ethical given the vulnerabilities of a dementia population.  
 
The post diagnosis recruitment may have also contributed to the non-significant findings as this 
introduced a time delay between initial assessments and being contacted about the research, in 
some cases up to 4 months. Thus, participants may have advanced in their dementia from when 
the referral was made. This was also reflected in ACE-III scores where a small but significant 
number of participants were scoring below 70 at the research appointment after scoring above 
this at initial screening. However, assessment for dementia can be an uncertain time for patients 
creating distress and anxiety (Lecouturier et al, 2008). For this reason the National Ethics 
Committee felt it was unethical to conduct the study prior to the participants being disclosed a 
diagnosis of dementia. Furthermore, despite the time delay, when exploring the data of 
participants with low ACE-III scores they appeared to perform relatively well on 4MT despite 
cognitive impairment suggesting minimal impact to the findings.   
 
There were also limitations with conducting the majority of the research in a participant’s home 
environment. The lack of consistent and distraction free environment may have interfered with 
performance on neuropsychological testing and thus reduced the internal validity of the 
findings.  However, restricting testing to the memory service would reduced the 
representativeness of the sample as it would have meant excluding the more frail participants 
who would have struggled to travel for an appointment. Ideally, being able to fund all 
participants to come to the memory service in pre-arranged transport would have enabled a 
more consistent research environment that may have increased validity and reliability, however, 
this was beyond the resources of this study.  
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It is well evidenced that low mood and anxiety can interfere with performance on cognitive tests 
(Beaudreau & O’Hara, 2009) and memory (Burt et al, 1995; Eysenck and Calvo, 1992). 
Although there was no significant relationship between anxiety and depression on 4MT 
performance, individual analysis of the scores suggests that some participants were within 
clinical range. Furthermore, disclosure of a dementia diagnosis has been associated with 
negative emotional reactions including low mood and anxiety in some people (De Lepeleire, 
Buntinx & Aertgeerts, 2004). Although efforts were made to exclude participants with mental 
health difficulties at initial screening there is a possibility that such psychological difficulties 
impacted performance on 4MT and the other cognitive tests. Tighter exclusion of participants 
with these symptoms may have increased the validity of the current findings i.e. incorporating 
depression and anxiety screening questionnaires prior to testing. However, given the overall 
non-significance of clinical symptoms in the sample, indicated by the HADs questionnaire, 
these effects may have been minimal.  
 
The current study aimed to understand the clinical utility of the 4MT and therefore was 
concerned with performance across the clinical groups. Therefore it was not deemed necessary 
to collect a control comparison group in light of resource being limited and time restrained. The 
clinical 4MT data was compared to the Bird et al (2010) control data in the absence of the 
control group in the current study. However, there were differences in demographic and 
neuropsychological characteristics of the Bird control group when compared to the AD and 
other dementia type group in the current study that reduced the reliability of the comparisons 
and therefore limit the inferences that can be drawn from the significant findings. Ageing is 
known to cause an increasing decline in cognitive abilities including memory (Peters, 2006). 
The Bird control group was comprised of younger participants than the clinical groups in the 
current study and therefore a less impaired cognitive baseline that may have enhanced 
performance on the 4MT and other neuropsychological tests. Furthermore, the Bird control 
group also had superior estimated premorbid functioning, which is considered a protective 
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factor against cognitive decline (Peters, 2006) and may have further enhanced performance on 
the measures. These differences affect the reliability of the comparisons and therefore the 
significant differences found between controls data and the clinical groups should be interpreted 
with caution. It would be helpful to replicate this study using a control group matched to the 
clinical groups in terms of demographic variables.  
 
Clinical implication 
The results of the study provide conflicting evidence to previous research that suggested the 
usefulness of the 4MT as a potential tool to facilitate early AD diagnosis. This study 
demonstrates that the 4MT appears to encounter difficulties differentiating between the two 
most common forms of dementia; AD and VD. This therefore raises the question whether the 
4MT is as applicable as previously suggested to a clinical setting where these presentations are 
common as well as often more complex and less clearly defined. In of light of the current 
findings, to fully understand the 4MTs potential as a clinical tool to aid early diagnosis of AD 
further research is needed and helpful ideas for this are discussed below. Researchers have 
raised a need for a more ecological assessment of spatial abilities that reflect real life situations 
as it was felt that most traditional tests are insensitive to topographical disorientation (Nadolne 
& Stringer, 2001). The 4MT is a tool that simulates a more ecological situation, however, it is 
clear that further studies applying this test to clinical settings is needed prior to drawing 
conclusions regarding clinical utility.  
 
These findings also raise the wider issue in translating laboratory design tests into clinical 
settings. The 4MT was developed in a controlled test environments where it was possible to 
conduct vigorous diagnostic assessment, make more definitive and clear diagnosis and utilise 
homogeneous samples. However, these laboratory settings are not reflective of clinical settings 
where presentations are complex and diverse, resource is limited and administration takes place 
in less than perfect environments (i.e. patient’s home). The findings of this study highlight the 
need for researchers to consider the ecological validity issues posed when developing tests, such 
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as 4MT, in laboratory settings. The design of the 4MT attempted to overcome issues of 
ecological validity by using stimuli that reflect real world settings (i.e. mountain landscapes). 
However, future early diagnostic tests would benefit from being developed within clinical 
settings where environments more closely resemble those found in these settings (i.e. 
heterogeneous samples, brief completion time). This would increase ecological validity, 
enhance clinical utility and provide tools that can operate more effectively in clinical practice.  
 
As discussed previously, past studies using the 4MT did not include a VD group, unlike the 
current study. A number of previous studies have reported evidence of significant hippocampal 
atrophy in vascular dementia (Laakso et al, 1996; Barber et al, 2000; Hanyu et al, 2000; Fein et 
al, 2000; Du et al, 2002; Gainotti et al, 2004; Burton et al, 2009). This has led to a new subtype 
of VD being proposed known as subcortical VD (Erkinjuntti et al, 2000), which is presumed to 
be the most common type of vascular dementia (van de Pol, 2011). The non-significant 
differences on 4MT performance between the AD and VD groups provides further evidence for 
hippocampal atrophy in VD. The findings therefore support the need for more well-defined and 
homogeneous subtypes of VD, such as subcortical VD, in order to enable more predictable 
clinical presentation, outcome and treatment responses (Erkinjuntti et al, 2000). This raises 
significant questions for the effectiveness of tests of allocentric memory impairment in early 
dementia diagnosis that merit further investigation. 
 
There is a growing interest in the early diagnosis of dementia in order to enable patients and 
their families access timely information and advice, useful medical and psychosocial 
interventions, and allow planning about future care (Prince et al, 2011; Department of Health, 
2012). This study supports and adds to this evidence base, but there are ethical dilemmas posed 
with the advancement of early diagnostic tools when the available treatments only delay 
symptoms for a relatively short period of time. It is important to acknowledge the potential 
dilemmas associated with early dementia screening. Early diagnosis of dementia has been 
associated with anxiety, depression and even suicide in patients (Draper et al, 2010). Other 
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potential negative implications include difficulties with sustaining employment and purchasing 
insurance, as well as a reduced sense of autonomy, self-image and overall quality of life (Lliffe, 
Manthorpe & Eden, 2003; Mattison, Brax & Zetterberg, 2010). Early diagnosis may also impact 
negatively on carers and family members, in terms of feelings of shame, stigma and isolation, 
and in changing the relationship with the patient (Mattison, Brax & Zetterberg, 2010). 
Furthermore, some of these emotional and practical challenges have also been found to occur 
within an MCI population, a diagnosis that is rising as a result of the emphasis on assessing 
people earlier for dementia (Dean & Wilcock, 2012). It is important therefore that the early 
diagnostic research is balanced with research investigating the associated potential risks and 
adverse consequences to guarantee ethical and thoughtful practice.  
 
Future Research  
To overcome the issues with power discussed above and allow for more conclusive findings it 
would be helpful to replicate this study with a higher sample size. However, alongside this it 
would also be beneficial to include a larger VD and MCI group as well as participants who did 
not received a diagnosis as an additional comparison group. Furthermore, administering the 
4MT prior to diagnosis of dementia and as early in the disease as possible would enabled further 
understanding of its clinical use in aiding early diagnosis of AD. For example, replication of the 
study within a primary care setting when a patient first reports memory symptoms to the GP 
would enable access to participants at early stages of dementia. However, it is likely that the 
same ethical dilemmas would arise and careful consideration is needed. Furthermore, to make 
more firm conclusions about causal relationships it would be helpful to incorporate a 
longitudinal aspect with administration of 4MT through the course of dementia progression. 
This would enable understanding of how performance changes as the disease progresses across 
the different dementias. 
 
Another helpful future direction for this research project would be to match MRI scans to data 
collected of those participants whom had one conducted at the initial assessment. This would 
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enable a deeper understanding of the non-significant differences in 4MT scores and the 
relationship to hippocampal atrophy. Furthermore, this would hopefully provide more 
understanding of the clinical utility of the 4MT to differentiate between AD and VD with 
regards to overlap in brain pathology. Furthermore, including a test that is able to control and 
manipulate the egocentric point of view would allow for the evaluation of whether AD spatial 
deficits are linked to difficulties with storing an allocentric map or the translation between the 
different spatial representations.  
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Introduction 
This paper provides a reflection on the process of conducting research exploring the clinical 
utility of a newly developed hippocampal reliant instrument to support the early diagnosis of 
AD and differentiate it from other forms of dementia within a memory service. The discussion 
will draw on my initial motivations for the project. I will then discuss the value of non-
significant findings in research with reference to the study results. I will also discuss the merits 
of using computerised tests such as the 4MT to aid dementia diagnosis. Finally, I will reflect on 
the dilemmas faced when setting up and conducting the study and consider the influence this 
process has had on my wider clinical practice.   
 
My initial motivation for the project 
The World Health Organisation (2012) recognise dementia as a global health challenge and the 
numbers of people living with dementia is expected to double every 20 years. The UK 
government have begun to recognise the importance of dementia research to make 
improvements in diagnosis and management. During my clinical training it became apparent 
how clinical psychology can significantly contribute to this evidence base.  Furthermore, like 
many others, I have experienced dementia within my own family adding to my interest in 
dementia research. I therefore took the opportunity to undertake my own research in this 
exciting and developing area making a contribution to improving the lives of people with 
dementia and those who care for them.  
 
Equating non significance with insignificance 
Generally, in psychological research it is difficult to publish non-significant findings, 
particularly in high tier journals. Statistical significance is a useful way to screen out 
manuscripts and deal with the high demand submitted to academic journals. However, this has 
created bias in the literature towards studies that find statically significant results. For example, 
research demonstrated how non-significant versions of otherwise identical manuscripts were 3 
times more likely to be rejected than the significant versions of the manuscript by consulting 
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editors for APA journals (Atkinson, Furlong, & Wampold, 1982). This publishing bias has long 
been problematic as it increases the frequency of Type I errors published thus creating 
unrepresentative and a potentially misleading evidence base (Pagell et al, 2009). Furthermore, 
the reliance on statistical significance to define study value leads to overall quality and 
contribution being neglected.  
 
The process of conducting a study from start to finish, which subsequently resulted in non-
significant findings caused me to reflect on this superiority of statistical significance. When I 
analysed my results for the first time I was initially filled with dejection and disappointment on 
finding the research hypotheses were not supported by significant results. However, on 
discussion with my thesis supervisors, I began to realise my non-significant findings potentially 
provided valuable information about the application of the 4MT in a clinical setting. Although 
there were clear flaws in the methodology of the study i.e. it was underpowered, the 4MT was 
potentially not as useful in differentiating between AD and other types, especially VD, in a 
clinical setting as previously implied from previous research. Thus, the results offered meaning 
i.e. that in a clinical setting the 4MT appears to have small or no effect in opposition to 
laboratory based findings (Hartley et al, 2007; Bird et al, 2010) that would benefit from future 
research. 
 
This research process has therefore taught me that non-significant findings can create potential 
avenues for future research that may otherwise remain unexplored. Furthermore, it prevents 
replication of unhelpful research saving valuable time and resources that could be applied to 
other research ventures. As a result of this experience in my future career I will endeavour to 
challenge this long held assumption and increase understanding of the potential value of such 
results so it can be more integrated into the literature. However, I am also aware that not all 
studies with non-significant results are worth publishing and that a balance needs to be struck to 
reduce the publishing bias.  
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Use of a Computerised Test 
The 4MT can be presented as a computerised test, as it was in this study. Although to reduce 
confounding influence of computer illiteracy the researcher interacted with the computer. The 
4MT is just one example of how developments in technology have enabled the production of 
new computerized testing tools. Paper and pencil tests are still widely used and are central to 
neuropsychological assessment of dementia due to high validity and reliability (Lezak, 2004). 
However, it has been suggested that computerised tests overcome a number of the challenges 
presented by pen and paper tests. These include the ability to alternate the administration form 
(Fichman et al, 2008), conduct automatic scoring (Fredrickson et al, 2010), reduce researcher 
interaction and involvement (Woo, 2008), provide accurate time control of stimuli presentation 
and measurement of motor response accuracy (Witt, Alpherts & Helmstaedter, 2013). 
Computerised tests can also enable the measuring and monitoring of cognition at home thus 
indicating potential decline in aging people and facilitating early diagnosis of dementia (Canini 
et al, 2014). Studies, such as this one, are therefore important and valuable as they aid the 
understanding of the utility of the 4MT, a computerised instrument that could have the potential 
to aid early diagnosis of and intervention in AD.  The results of this study did not provide firm 
conclusions about the 4MTs clinical utility but demonstrate that further research would be 
worthwhile to fully understand the role it could play in aiding early AD diagnosis and 
differentiating it from other forms of dementia.  
 
 
Dealing with dilemmas  
Through the planning, recruitment and analysis phases of the research project I have learnt 
many important lessons about how to effectively undertake research across NHS clinical 
services. I have also experienced a number of dilemmas when conducting research within a 
dementia population and encountered a number of unanticipated obstacles at different stages 
thus learning the importance of remaining flexible in my approach to resolve them.  I will now 
take this opportunity to discuss some examples of this.   
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The most significant flaw in the study is the underpowered sample size, which arose due to 
difficulties encountered with recruitment highlighting the challenges of conducting research in 
clinical settings. During the planning stages of the study, referral rates and caseloads suggested 
that enough participants could be recruited to enable the regression analysis.  Furthermore, I 
was integrated into the team with a clinical placement in the services enabling the opportunity to 
remind clinicians about the study and identifying potential participants.  The research register 
form was included in the assessment packs and clinicians agreed to ask patients to complete this 
at the time of the initial assessment. I reminded clinicians regularly in team meetings to ask 
patients to complete the form where appropriate. Although many of the clinicians made an 
active effort to get these forms completed, it was difficult for others to remember them in the 
midst of the essential assessment paper work. I learnt quickly that despite good intentions and 
support from the staff, relying on busy clinicians to recall the form when they have other 
clinical priorities was going to become an issue for the sample size. In anticipation of this we 
had permission to invite existing clients from clinician’s caseloads but with the involved 
clinician needing to make contact with the patient first to gain their consent. Again, the reliance 
on clinicians posed somewhat of an issue but this appeared to be overcome by the strong 
working relationships I forged during my clinical placement. However, I leant a valuable lesson 
to integrate a variety of recruitment pathways into a study to provide options should any barriers 
arise, as it did in this study, and maximise sample size.  
 
Another unforeseen recruitment issue that arose half way through the data collection was that 
the memory services went through significant management and frontline staff changes. This 
increased the time taken for patients to be allocated to a clinician for a diagnosis disclosure, 
reducing the amount of participants ready to contact as participants needed to have a disclosed 
diagnosis to take part. This meant that the recruitment rate became slower than had been 
anticipated and resulted in a reduction in the sample size. To add to this, both dementia advisors 
also left their posts creating a further lull in potential participants. I became more present in the 
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service and continued to promote the project to the staff team in a hope for more participants. 
However, unfortunately there was relatively little I could do to overcome this issue other than 
wait for new members of staff to start at the service. This meant extending the time frame for 
data collection. However, this was worth doing in order to maximise sample size and minimise 
the findings being significantly underpowered. Unfortunately, the thesis timeframes needed to 
be observed and recruitment had to eventually be terminated despite not reaching the desired 
sample size. 
 
As recruitment for the study was undertaken within NHS clinical services, I gained my first 
experience of submitting a research proposal for NHS ethical review. People with dementia are 
considered a vulnerable population and this presented us with complex ethical issues during the 
planning of this study. Compromises had to be made with the methodological design quality to 
ensure that the research being conducted was ethical. The most significant of these was the 
ethical requirement that participants could only be recruited following the disclosure of their 
diagnosis, which may have limited the findings of this study. However, precautions were taken 
to maximise validity, such as the researchers being blind to diagnosis and excluding people who 
were moderately to significantly impaired at time of diagnosis (i.e. ACE-III scores below 70). It 
was also considered a clinically beneficial study to conduct with potentially valuable findings 
despite the compromises to study design quality.  
 
Furthermore, there were also issues relating to the validity and reliability of neuropsychological 
testing in this study. The length of neuropsychological battery had to be limited to minimise 
tiredness and fatigue to which the elderly are more susceptible. The testing was therefore 
matched to a normal set of neuropsychological tests used in routine clinical practice. However, 
this meant reducing the amount of potential confounding variables controlled for thus reducing 
the methodological quality.  
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Furthermore, to maximise cognitive performance on neuropsychological testing it is usually 
conducted in a formal setting with minimal distractions and interference increasing the validity 
and reliability of the scores. The dementia population tend to experience difficulties 
independently travelling to the memory service due to the cognitive impairment and physical 
health difficulties. It was decided to conduct the testing at the participant’s home where 
preferable to minimise burden to the participants and their carer/s. During testing, a number of 
interruptions and distractions often occurred (i.e. telephone or door ringing), which may have 
interfered with performance on these tests. However, minimising disruptions to participant’s 
daily routines was considered to outweigh the need for creating a consistent research 
environment. It also enabled participants to be more comfortable in home surrounding and 
reduce anxiety and dementia related confusion, which are known to impact neuropsychological 
performance (Larson et al, 2009). Furthermore, by conducting the research at the memory 
service many of the more frail participants would have not taken part in the study. This may 
have introduced bias into the sample as we would have mainly recruited physically healthier 
and younger participants as well as those potentially with strong motivation to take part.  
 
Memory impairment also added to difficulties when working with people with dementia. There 
were a number of occasions when participants forgot the appointment. Where possible I would 
ring the participants in the morning to remind them of the appointment but despite this some 
participants still did not remember. This was at times frustrating particularly when recruitment 
numbers were reduced (see below) as it wasted valuable time and cost in travelling to locations 
around London. This further added to the reduced sample size. 
 
Gaining informed consent from people with dementia is a key issue facing all research in this 
field. The process implies the person having capacity to understand the significant benefits, 
risks and alternatives of the proposed assessment to then make and communicate a decision 
(Uniform Health Care Decisions Act of 1993, 1994). Compromised cognitive ability to make 
health care decisions is often affected by dementia. Special measures had to be taken to ensure 
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participants were able to provide informed consent in this study. Information sheets were 
developed in line with Easy Read Guidance (2010), a Department of Health Strategy for making 
information more accessible for people with learning disabilities. These were also designed in 
consultation with people with dementia to ensure that the information was clear and accessible. 
Capacity to consent was assessed by the involved clinicians but also repeated on the day of 
testing. Time was spent before the testing to ensure the participants understood the aims and 
their involvement in the study. This added to the demands of the study and the length of the 
home visit, however, it was an essential ethical component to the study. The inclusion of assent 
procedures to gain consent from carers in light of a participant lacking this capacity was 
considered but not implemented given the interest in the early phases of the dementia where we 
would assume capacity remains.  
 
Reflecting upon the literature review and the empirical paper the limitations posed by the cross-
sectional design of the studies in the literature review were also relevant to the empirical paper.  
These include correlations not offering causal effects, small sample sizes and possible 
confounding variables. These limitations clearly have implications on the conclusions made in 
the empirical paper. When writing the literature review it was notable that longitudinal study 
designs could reduce the limitations posed and enabled more valid findings. However, whilst 
undertaking my own research I experienced first-hand some of the challenges of conducting 
research with regards to recruitment, ethics and analysis described above. Furthermore, to 
conduct a large scale longitudinal study would have required a significant amount of resources 
and time that would have been beyond the scope of a doctorate in clinical psychology thesis.  
 
Implications for clinical practice 
There is a prevailing negative stereotype of people with dementia and misconceptions about the 
disease mainly of incapacitation and dependency (Batsch & Mittelman, 2012). It has been 
suggested that it is stigma that creates the largest barrier to early diagnosis and intervention 
(Prince, Bryce & Ferri et al, 2011). It prevents people from acknowledging symptoms and 
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obtaining the help they need to improve cognition and continue to live a good quality of life 
(Zebrowitz, & Montepare, 2000; Nelson, 2008). Thus, dementia remains significantly under 
diagnosed within the UK as well as worldwide (Prince, Bryce & Ferri et al, 2011). It has also 
been demonstrated that many health care professionals are reluctant to give the label of 
dementia due to this stigma, which further prevents the early evaluation of cognitive function 
(Koch & Ilffe, 2010; Werner & Giveon, 2008). It has been argued that early diagnosis has the 
potential to change the way society views and approaches dementia (Prince, Bryce & Ferri et al, 
2011). Furthermore, it can empower people with dementia by allowing them to fully participate 
in the planning of their own lives and make important decisions about their future care.  
 
This study therefore plays an important role in aiding early diagnosis and therefore indirectly 
challenging stigma. The process of conducting a thesis into the early phases of dementia 
challenged many of my pre-existing assumptions about this population. On reflection, I am 
aware that perhaps I was also susceptible to these negative perceptions. I wonder now whether 
this was creating me to feel apprehensive when making a diagnosis of dementia in my own 
clinical work. However, meeting with the many participants across my research I saw that many 
were living content and independent lives. A number of the participants even commented to me 
about their dislike of word dementia due to the associated stigma, which was not their actual 
lived experience. This experience taught me about the important need to challenge this stigma to 
maximise the benefits of early diagnostic research and reduce the barrier it poses to engaging in 
helpful interventions. This notion is further supported by the literature review were some 
evidence demonstrated minimal differences in QoL between people with dementia and those 
with MCI or normal cognition.  
 
As a Trainee Clinical Psychologists we are expected to learn skills as a clinician and a 
researcher. On interaction with participants a conscious effort had to be made to retain research 
boundaries e.g. following instructions verbatim for each participant to ensure the research 
findings were as valid and reliable as possible. This was particularly difficult when participants 
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raised concerns, such as isolation. A conscious effort needed to be made to prevent a move into 
clinician mode and exploring concerns further as I would in a clinical meeting. Instead, I would 
signpost the participant to their relevant clinican. However, having a strong repertoire of clinical 
skills had benefits such as enabling better participant engagement in research. 
 
Finally, there were many participants who reported to find the research appointments enjoyable 
and empowering that was linked to a desire to give back to others. I was humbled by the 
willingness of people to participate in this research with the sole motivation that it might 
improve the lives of others with dementia but potentially not there own. This demonstrates the 
value of conducting research with this population, as it does not just appear to have academic 
gains but potentially clinical gains for the individual. 
 
Conclusions 
Conducting research in the field of dementia is challenging. It requires careful thought into how 
to work with and think sensitively about the person’s needs. The emotional impact of working 
with people who are undergoing the assessment process should also not be minimised. Despite 
this, the work was extremely rewarding and inspiring. Supporting research that facilitates the 
early diagnosis of dementia enables access to effective treatments to improve cognitive 
functioning, emotional well-being and quality of life for people with dementia and those who 
care for them. There is much that remains unknown about dementia and differential diagnosis in 
the earliest phases still remains a challenge that needs to be addressed. This thesis, despite its 
limitations, is therefore considered important in advancing instruments that aid the identification 
of early AD from other forms of dementia and better understand the underlying changes to the 
brain and cognition.  
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RESEARCH DEPARTMENT OF CLINICAL, 
EDUCATIONAL AND HEALTH 
PSYCHOLOGY 
!
!
!
 
Stage 1 Participant Information Sheet- Clinical Sample 
 
Can people with memory difficulties and dementia do 'Cognitive behaviour therapy' (CBT) 
 
We would like to invite you to take part in our research study. Before you decide, we would like 
you to understand why the research is being done and what it would involve for you. One of our 
team will go through the information sheet with you and answer any questions you have. This 
will take 10 minutes. Talk to others about the study if you wish. Part 1 will tell you the purpose 
of this study and what will happen to you if you take part. Part 2 will give you more detailed 
information about the conduct of the study. Ask us if there is anything that is not clear. 
 
PART 1 
 
What is the purpose of the study? 
We are researching early diagnosis and therapy for people with dementia or memory 
difficulties. There are two main reasons for doing this study: 
 
1. People with dementia/memory difficulties can often feel quite depressed or anxious. 
Sometimes they are offered a type of counseling called CBT to help them with this. However, 
elements of CBT can be quite difficult for some people to understand. The aim of this study is 
to see how easy it is for people with dementia/memory difficulties to understand the different 
parts of CBT. 
 
2. It is hard to diagnose dementias early. To help us identify people with dementia we use pencil 
! )"$!
and paper tests of memory and other abilities. This study will look at whether a newly 
developed pencil and paper test called 'four mountains' helps us spot early Alzheimer's disease 
compared to other dementias. 
 
Why have I been invited? 
You have been invited because you are over 50 and have problems with your memory or 
dementia. We are inviting some people who have memory difficulties or dementia and some 
people who don’t to take part in the study so that we can look at differences between them.  
 
Do I have to take part? 
It is up to you to decide to join the study. We will describe the study and go through this 
information sheet. If you agree to take part, we will then ask you to sign a consent form. You 
can change your mind at any time and withdraw from the study.  This will not affect your care. 
 
What will happen if I take part? 
You will meet with a researcher for one to one and a half hours. The researcher will meet with 
you in a place of your choosing, generally our clinic or your home. 
 
Expenses 
Participants who travel to the clinic for the research will be reimbursed for the full cost their 
journey.  
 
What will I have to do? 
The research will involve filling in some questionnaires and doing some pencil and paper tasks 
to look at memory and other abilities.  
 
What are the possible disadvantages and risks of taking part? 
We will be giving you some questionnaires and pencil and paper tasks. While we don't think it 
is likely, this might make you feel worried or distressed. If this were the case you could stop the 
research at any time. We would also discuss with you what sources of support are available and 
direct you to them. You may have questions about your current clinical care from the service or 
your current diagnosis. We cannot offer any clinical advice during the research but we will 
direct you to someone who can answer any questions.   
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What are the possible benefits of taking part? 
We cannot promise the study will help you but we hope the information we get from this study 
will help improve the treatment of people with dementia and memory difficulties. Some people 
have also told us they enjoy the process of doing the questionnaires and pencil and paper tests. 
 
What happens when the research study stops? 
After you have taken part the researcher may ask you if you are interested in taking part in the 
second stage of this study. It will involve another hour of testing either at your home or at the 
clinic where you will complete questionnaires and a short interview about a recent life event. 
Information sheets about the second part of the study will be provided at the end of the research 
session to help you decide whether to take part. You will have time to take this away and think 
about your decision. A smaller number of people are needed for this second part of this study so 
when we have enough people for stage 2 we will stop asking people if they want to take part in 
this. 
 
If you are interested in how you have done on the questionnaires and tasks then we can provide 
you with individualised feedback. You can contact Dr Joshua Stott on 0207 679 5950 or Lucy 
Gore on 07801536706 if you want this. 
 
You and all other participants will be invited to a feedback session once the study is completed. 
At this session, we will present what we have found and answer questions you may have about 
the research.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2.  
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2.  
 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision.  
 
PART 2 
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What if relevant new information becomes available?  
If the study is stopped for any reason, we will tell you and arrange your continuing care.  
 
What will happen if I don't want to carry on with the study? 
You can withdraw from the study at any time and this will not affect your usual care. We will 
discuss with you whether you want all of your information withdrawn from the study.  
 
What if there is a problem? 
If you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated by members of staff you may have experienced due to your participation 
in the research, National Health Service or UCL complaints mechanisms are available to you 
(please see harm section below). Please ask your researcher if you would like more information 
on this.  
 
Harm 
In the event that something does go wrong and you are harmed during the research and this is 
due to someone‘s negligence then you may have grounds for a legal action for compensation 
against University College London but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to you. 
 
If you suspect that the harm is the result of the Sponsor’s (University College London) or the 
hospital's negligence then you may be able to claim compensation.  After discussing with your 
researcher, please make the claim in writing to Dr Joshua Stott who is the Chief Investigator for 
the research and is based at UCL. The Chief Investigator will then pass the claim to the 
Sponsor’s Insurers, via the Sponsor’s office. You may have to bear the costs of the legal action 
initially, and you should consult a lawyer about this. 
 
If you suspect harm is the result of the National Health Service and wish to make a formal 
complaint, you can do this by conducting the Patient Advice and Liaison Service who can offer 
advice on the best service to address your complaint. They can be contacted on 
pals.cnwl@nhs.net or 020 3214 5773.  
 
Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of the research will be kept 
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strictly confidential, and any information about you which leaves the hospital/surgery will have 
your name and address removed so that you cannot be recognised.  We will keep this data 
stored securely for 5 years and it will only be look at by the research team.  
 
If you decide to take part in the study we will write to your GP to let them know about your 
involvement in the study. We will explain in the letter what participating in the study will 
involve and that you have made an informed decision after being made aware of what it will 
involve and your rights as a participant.  
 
What will happen to the results of the research study? 
The results of the research may be published in scientific journals. You will not be identified in 
any data or report unless you have given your consent 
 
Who is organising and funding the research? 
The research is organized and funded by University College London and, Central and North 
West London NHS Trust. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given favourable 
opinion by the National Research Ethics Committee. This particular research has also been 
reviewed and approved by academic staff at University College London. 
 
Further information and contact details 
If you want further information about the study or have any concerns about it, please do contact 
Dr Joshua Stott on or Lucy Gore on  
!
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Appendix 6: Participant Consent Form 
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Appendix 7: Supplemental Correlation Tables 
 
Supplemental Table 1: Pearsons Correlation for all measured variables split by AD (N=16) versus 
Other Dementia (N=19) 
*  Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed. 
AD 
 ACE total 
Memory Attention Language Fluency Visuospatial TOPF TMT A TMT B Anxiety Depression 4MT 
ACE total 1            
Memory  .861** 1           
Attention .528 .500 1          
Language .606* .412 -.194 1         
Fluency  .708** .572 .236 .450 1        
Visuospatial .713** .366 .213 .593* .487 1       
TOPF .368 .187 .250 .268 .110 .364 1      
TMT A .237 .156 -.251 .431 .657* .324 .313 1     
TMT B  .545 .448 .169 .365 .790** .539 .409* .530 1    
Depression -.162 -.029 -.184 -.220 .076 -.363 -.568* -.162 -.254 1   
A -.090 .081 .187 -.271 -.505 -.373 -.189 -.785** -.687* .147 1  
4MT -.195 -.035 .344 -.299 .022 -.516 .101 -.238 .286 .009 .008 1 
Other dementia type  
 ACE total 
Memory Attention Language Fluency Visuospatial TOPF TMT A TMT B Anxiety Depression 4MT 
ACE total -            
Memory  .807** -           
Attention .877** .698** -          
Language .873** .550* .734** -         
Fluency  .799** .441 .623** .715** -        
Visuospatial .647** .557* .446 .403 .449 -       
TOPF .856** .691** .767** .770** .677** .569* -      
TMT A .312 .014 .112 .269 .692** .294 .273 -     
TMT B  .284 .067 .170 .226 .433 .371 .355 .598** -    
Anxiety -.455 -.458 -.323 -.427 -.394 -.066 -.516* -.219 -.099 -   
Depression -.459 -.138 -.219 -.617** -.606** -.223 -.540* -.679** -.476* .458 -  
4MT .312 .016 .285 .353 .249 .477* .319 .325 .541* -.088 -.397 - 
 
 
! )#+!
Supplemental Table 3: Pearsons Correlation for all measured variables split by AD (N= 15) versus VD 
(N=9) 
*  Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed. 
 
AD  
 ACE total 
Memory Attention Language Fluency Visuospatial TOPF TMT A TMT B 
Anxiety Depression 4MT 
ACE total 1            
Memory  .854** 1           
Attention .571* .529* 1          
Language .635* .462 -.091 1         
Fluency  .685** .574* .242 .459 1        
Visuospatial .501 .124 .161 .349 .248 1       
TOPF .190 .057 .094 .127 .084 .153 1      
TMT A .174 .012 -.167 .329 .466 .382 .240 1     
TMT B  .472 .392 .127 .272 .727** .522 .447 .306 1    
Depression .002 .136 .225 -.187 -.456 -.146 -.288 -.711** -.503 1   
Anxiety .010 .048 -.023 -.095 .030 .061 -.611* -.173 -.079 .356 1  
4MT .021 .041 .315 -.119 -.03 .110 -.161 -.222 .352 .285 .460 1 
VD 
 ACE total 
Memory Attention Language Fluency Visuospatial TOPF TMT A TMT B 
Anxiety Depression 4MT 
ACE total 1            
Memory  .890** 1           
Attention .891** .818** 1          
Language .935** .753* .835** 1         
Fluency  .805** .566 .553 .737* 1        
Visuospatial .784* .546 .685* .698* .680* 1       
TOPF .885 .767* .899** .821** .716* .652 1      
TMT A .377 .051 .025 .376 .734* .509 .253 1     
TMT B  .384 .250 .411 .302 .295 .525 .444 .633 1    
Anxiety -.200 -.272 .398 -.215 -.207 .202 .050 -.781* -.576 1   
Depression -.435 -.566 -.437 -.296 .373 -.044 -.607 -.300 -.563 .464 1  
4MT .417 .185 .600 -.439 .237 .619 .372 .338 .648 .281 -.011 1 
